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ABSTRACT 
Ewing sarcoma is an aggressive and deadly bone and soft tissue cancer 
predominantly effecting the pediatric population. While intensification of 
chemotherapy has improved the outlook for patients with localized disease, little 
progress has been made for patients with metastatic or relapsed disease.  The 
prognosis for these patients remains dismal, with fewer than 20% surviving. 
However, little is known about the biological mechanisms driving Ewing sarcoma 
metastasis and in order to improve outcomes for Ewing sarcoma patients, it is 
imperative that we understand these metastatic processes.  The chemokine 
receptor, CXCR4, is the most commonly expressed chemokine receptor in 
human cancer. There is evidence demonstrating that the CXCL12/CXCR4 
signaling axis contributes to tumor metastasis in over twenty human 
malignancies but its function in Ewing sarcoma is not yet known.  Through the 
work of this thesis, we sought to investigate the role of the CXCL12/CXCR4 
signaling axis as a mediator of Ewing sarcoma metastasis. 
Evaluation of CXCR4 transcript and surface protein in Ewing sarcoma cell 
lines and primary tumors revealed variability of CXCR4, ranging from 
undetectable expression to high-level expression. We have demonstrated the 
highly dynamic nature of CXCR4 expression in Ewing sarcoma cells and have 
shown that this molecular plasticity allows Ewing sarcoma to switch back and 
forth between CXCR4- and CXCR4+ states in response to changes in the 
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microenvironment.  Significantly, Ewing sarcoma cells that express high levels of 
CXCR4 are highly migratory and invasive toward a CXCL12 gradient. The 
CXCR4 antagonist, AMD3100, impeded the migratory and invasive properties of 
the CXCR4+ cells. 
Having demonstrated that CXCR4 is dynamic and that its expression is 
induced in response to microenvironmental cues we investigated the potential 
contribution of epigenetic regulation to these cell-state transitions.  Chromatin 
immunoprecipitation studies revealed that the CXCR4 promoter exists in a 
bivalent state, as characterized by simultaneous enrichment of the activating, 
H3K4me3, and the repressive, H3K27me3 marks at the CXCR4 promoter.  Of 
significance, exposure of Ewing sarcoma cells to microenvironmental cues 
resulted in loss of bivalency, as evidenced by loss of H3K27me3 and retention of 
the H3K4me3. Additionally, we demonstrated that an active enhancer exists 
upstream of CXCR4 and also contributes to CXCR4 regulation.  In support of 
this, treatment of Ewing sarcoma cells with the bromodomain inhibitor, JQ1, 
resulted in marked down-regulation of CXCR4 expression in ambient conditions 
and blocked stress-dependent induction.  These findings support the potential 
use of epigenetic modifiers as therapeutics that could be used to antagonize cell 
state transitions.  
This thesis reveals the highly plastic and dynamic nature of CXCR4 
expression in Ewing sarcoma and shows that cells transition between CXCR4- 
and CXCR4+ states in response to changes in the microenvironment.  These 
data support a model in which reversible, epigenetically-driven, cell state 
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transitions contribute to metastasis.  I have developed novel genetic and in vivo 
tools that will enable testing of this hypothesis in the future.  By elucidating 
mechanisms of CXCR4 regulation and the contribution of CXCL12/CXCR4 
signaling to Ewing sarcoma metastasis this thesis identifies new areas for 
biologic investigation and new opportunities for therapeutic intervention. 
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CHAPTER ONE 
 
INTRODUCTION 
 
Rationale 
Cancer represents a major public health problem and is a leading cause of 
morbidity and mortality worldwide (1). Additionally, this is reflected in pediatric 
population, as cancer is the number one cause of death by disease in children 
between the ages of 0 and 19 years in the U.S. (2).  Furthermore, metastasis 
accounts for 90% of cancer related deaths.  This thesis focuses on Ewing 
sarcoma, an aggressive and deadly pediatric cancer.  Ewing sarcoma is the 
second most common bone malignancy in children and young adults (3). Over 
the last several decades, the outcome for Ewing sarcoma patients with localized 
disease has improved; however for the quarter of patients who present with 
metastatic disease, the outcome remains dismal (4, 5).  Unfortunately these 
statistics are attributed to the lack of new therapies being developed to combat 
metastatic pediatric cancer as we are still trying to understand the molecular and 
cellular biology driving Ewing sarcoma metastasis.  
Chemokines and chemokine receptors play essential roles in many 
physiological processes with the most critical being the ability to induce 
chemotaxis.  Given this role in chemotaxis, there is a rich literature implicating 
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chemokines and their receptors in tumor metastasis (6, 7). One of the best-
studied chemokine and chemokine receptor pairs is CXCL12/CXCR4.  The 
CXCL12/CXCR4 signaling axis has been shown to contribute to tumor cell 
proliferation and angiogenesis (8-10). Furthermore, numerous studies 
demonstrate that CXCR4 expression is upregulated in metastatic tumors when 
compared to localized tumors (11, 12).  Despite this phenomenon being 
documented in many human malignancies, little is known about the contribution 
of CXCR4 to Ewing sarcoma metastasis.   Therefore, in this thesis we begin to 
investigate the contribution of CXCR4 to Ewing sarcoma metastasis. Defining the 
contribution of CXCR4 to Ewing sarcoma metastasis will provide a new 
understanding of the molecular mechanisms driving Ewing sarcoma with the long 
term hope of developing new therapeutic strategies to tackle metastatic disease.  
 
Ewing sarcoma 
Pathologist James Ewing first described Ewing sarcoma in the 1920s as a 
bone tumor, which he initially termed diffuse endothelioma (13).  Ewing sarcoma 
is an aggressive small round cell tumor of presumed stem cell origin affecting the 
bones and soft tissues. Although a rare tumor type with only an average of 200 
new cases in the United States per year, Ewing sarcoma is the second most 
common bone malignancy in children and young adults (14).  Ewing sarcoma 
has a predilection for males (1.6:1) and a peak incidence between the ages of 5 
and 25 (15).  Ewing sarcoma most commonly presents in the long bones (femur, 
humerus, and tibia), pelvis, and chest wall (16). The bone tumors preferentially 
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present in the adolescent patients whereas the soft tissue tumors preferentially 
present in the adult patients (17).   
 
Ewing sarcoma genetics 
Ewing sarcoma is genetically characterized by a somatic reciprocal 
translocation between the EWSR1 gene and an ETS family member, which is 
considered pathognomonic for the disease (18).  The translocation encodes a 
protein, which acts as an aberrant transcription factor that deregulates key genes 
involved in Ewing sarcoma oncogenesis (19).  About 85-90% of Ewing sarcoma 
cases have an EWS-FLI1 translocation between chromosome 11 and 22 
t(11;22)(q24;q12) (19, 20). Variant EWS-ETS fusions have been reported 
including EWS-ERG, EWS-ETV1, EWS-ETV4, and EWS-FEV (21-25).  In less 
than 1% of Ewing sarcoma patients, non-EWS fusions have been identified. 
These fusions occur between the TET (TLS/EWS/TAF15) family member, TLS 
and one of two ETS family members, ERG or FEV (26). Aside from the 
translocation, Ewing sarcoma tumors are typically genetically silent tumors with a 
low mutational burden; however, recurrent somatic mutations across Ewing 
sarcoma tumors and cell lines have been reported in STAG2 (20%), CDKN2A 
(12%), and TP53 (7%) (27-29).  
 
Ewing sarcoma treatment 
Ewing sarcoma is treated with aggressive multi-agent chemotherapy and 
local control.  A combination of neoadjuvant and adjuvant multi-agent systemic 
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chemotherapy consisting of vincristine, doxorubicin, and cyclophosphamide, and 
alternating rounds of ifosfamide and etoposide is considered the standard of care 
for Ewing sarcoma patients (30-32).  In addition to chemotherapy, aggressive 
local control measures including radiation and/or surgery are also part of 
standard care procedures.  However, as Ewing sarcoma is common in the axial 
skeleton, surgical resection is often times unachievable.  While this combination 
is often successful at controlling local, non-metastatic disease, unfortunately, 
there is a high level of toxicity associated with chemotherapeutic agents.  
Patients who do survive often suffer from debilitating or lethal health conditions 
including cardiovascular disease, growth abnormalities, infertility, and secondary 
malignancies (33-35).  
 
Ewing sarcoma prognosis 
Prior to the use of chemotherapy as treatment for Ewing sarcoma patients, 
survival was less than 10% (4). Intensification of therapy has led to five-year 
event-free survival (EFS) rates of 70-80% in patients with localized disease (4, 
5). Unfortunately, this progress has not yet been achieved for patients with 
metastatic disease. For the quarter of patients who present with metastatic 
disease at diagnosis the outcome is poor with five-year EFS of less than 30% (4, 
5).  Additionally, up to a third of patients who present with localized disease will 
relapse at distant sites following an initial clinical remission.  The outcomes for 
these patients are equally grim. Currently, aside from the presence of overt 
	   5	  
metastasis there is no way to predict which Ewing sarcoma patients will relapse 
and which will survive.  
 
Metastasis 
Metastasis is a complicated, multi-step process in which tumor cells 
spread from a primary location to a non-adjacent secondary location.  Metastasis 
is responsible for over 90% of cancer related deaths and, unfortunately, is the 
aspect of cancer pathogenesis that is least understood (36). In brief, the 
metastatic cascade consists of the following steps: tumor cells locally invade 
through the extracellular matrix (ECM), intravasate into the blood supply, survive 
and circulate through the vasculature, extravasate into the parenchyma of distant 
tissues, form micrometastatic colonies, and ultimately, generate macroscopic 
growths to complete the metastatic cascade (37).  Understanding the critical 
components contributing to the metastatic cascade is imperative in order to 
improve patient outcome.  Despite new discoveries, and an enhanced 
understanding of Ewing sarcoma biology, little remains known about the 
molecular mechanisms driving Ewing sarcoma metastasis.   
 
Chemokines 
Chemokines are chemotactic chemokines that are involved in many 
processes such as immune surveillance, inflammation, embryogenesis, 
angiogenesis, and every step of the metastatic cascade—the most critical being 
their ability to induce directed chemotaxis (6, 38-43).  To date, over 50 human 
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chemokines have been characterized along with over 20 chemokine receptors 
(summarized in Figure 1.1) (44).  
 
 
Figure 1.1. Chemokines and their receptors. A comprehensive list of the different classes of chemokines and the 
chemokine receptors, which they bind to.  There is chemokine redundancy with one chemokine binding multiple 
chemokine receptors.  This figure was adapted from (44).   
 
Chemokines are a family of small proteins with molecular weights ranging 
between 8 and 10 kD that generally share a common structural characteristic of 
conserved cysteine residues.  Chemokines are separated into four classes based 
on the arrangement of these cysteine residues, which help form their three-
dimensional structure: CC (β), CXC (α), CX3C (δ), and C (γ) (structures are 
summarized in Figure 1.2) (45).  The CC family is the largest chemokine family 
(28 members), the CXC family is the second largest family (17 members) and the 
CX3C and C families each have one member (44).  The two cysteines in the N-
terminus of the CC family are adjacent to each other, there is one amino acid 
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separating the cysteine residues in the CXC family, the CX3C has three amino 
acids separating the cysteines, and the C family has a single cysteine in the N 
terminus (45).   
 
Figure 1.2. Chemokine classes based on structure. Chemokines are separated into four groups based on the first two 
cysteine residues.  Typically (the C chemokines are the exception) four cysteine residues interact with the first and the 
third and the second and the fourth residues forming disulfide bonds.  Chemokines bind to chemokine receptors that also 
contain the same conserved structure. Adapted from (45). 
 
Functionally, chemokines are classified as either inflammatory or 
homeostatic.  Inflammatory chemokines are activated and recruit cells to the site 
of injury or inflammation whereas homeostatic chemokines are constitutively 
expressed (46).  Homeostatic chemokines are involved in more diverse functions 
than inflammatory chemokines such as secondary lymphoid tissue architecture 
as well as regulating hematopoietic cell trafficking (47).  In addition to their critical 
role in the immune system, cytokines have been known to play a role in a 
number of pathologies including cancer, rheumatoid arthritis, multiple sclerosis, 
vascular disease, pulmonary disease, Crohn’s disease, and human 
immunodeficiency virus-1 (HIV-1) infection (48-54). 
 
Chemokine receptors 
Chemokines function by binding to and subsequently activating surface 
bound G protein-coupled receptors (GPCRs).  GPCRs share a common, seven-
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transmembrane structure with seven helical regions connected by three 
extracellular and three intracellular loops (55). As with chemokines, the 
chemokine receptors are also broken into four classes—CCR, CXCR, CX3CR, 
and XCR, each of which contains two conserved cysteine residues that form a 
disulfide bond critical for ligand binding (summarized in Figure 1.1). As defined in 
their name, GPCRs are coupled with G proteins located on the inner surface of 
the plasma membrane. The G proteins are heterotrimeric, containing Gα, Gβ, 
and Gγ subunits (56, 57).  The Gα subunit has four family members: Gαs, Gαi, 
Gαq, and Gα12, with each family member imparting the GPCR signal through 
different signal transduction pathways (58, 59).  Under basal conditions, GDP 
(guanosine diphosphate) is bound to the Gα subunit, and the Gβ and Gγ 
subunits form a dimer. Upon chemokine binding, GPCRs undergo conformational 
changes, in which GTP (guanosine triphosphate) replaces GDP in the α subunit, 
displacing the Gβ/Gγ subunit from the GPCR (60).  The Gα and Gβ/Gγ subunits 
remain tethered to the plasma membrane but are no longer bound to the GPCR 
(60, 61) (signaling of G proteins is summarized in Figure 1.3). Multiple 
intracellular signaling pathways are activated upon chemokine binding such as 
MAPK (mitogen-activated protein kinase), and cAMP (cyclic adenosine 
monophosphate), and JNK (c-Jun N-terminal kinase) (62).  The signal remains 
active as long as GTP is bound to the Gα subunit, but can revert back to an 
inactive form when GTP is hydrolyzed back to GDP and the Gα and Gβ/Gγ 
subunits are re-associated with the GPCR.  GPCRs can also signal 
independently of G proteins (63).  
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Figure 1.3. Signaling through GPCRs. Under basal conditions, the Gβ/Gγ subunit (purple) and the Gα subunit (with 
GDP bound, orange) are tethered to the GPCR (green).  Upon chemokine binding, GDP is converted to GTP at the Gα 
subunit resulting in signal transmittance.  Upon GDP conversion, the Gα and Gβ/Gγ subunits are no longer bound to the 
GPCR.  The complex can reassemble back to the basal state (left side) upon hydrolysis of GTP back to GDP.  Adapted 
from (60). 
  
Like chemokines, chemokine receptors have been implicated in many 
diseases, including cancer (CXCR4, CCR4, CCR7, CCR10), HIV (CXCR4 and 
CCR5), multiple sclerosis (CCR2), and rheumatoid arthritis (CCR1) (64-68).  
GPCRs are considered to be highly druggable targets given their cellular 
location, role in many physiological processes, and their importance in disease.  
In fact, out of the currently available prescription and over-the-counter drugs, 30-
50% of them either directly or indirectly target GPCRs (69, 70).  CCR5 and 
CXCR4 antagonists have been successfully developed as drugs for HIV 
inhibition and stem cell mobilization, respectively (71, 72). 
 
CXCL12 and CXCR4 
One of the best-studied chemokine and chemokine receptor pair is 
CXCL12/CXCR4.  CXCR4 is a G-protein coupled chemokine receptor encoded 
by chemokine (C-X-C motif) receptor 4 on chromosome 2.  CXCR4 is widely 
expressed on cells in the immune and central nervous system, hematopoietic 
Chemokine 
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cells, as well as cells in the brain, lung, colon, heart, liver and kidney (62).  
CXCL12, also referred to as stromal cell-derived factor 1 (SDF-1), is encoded by 
chemokine (C-X-C motif) ligand 12 on chromosome 10 and is the sole 
chemokine for CXCR4.  CXCL12 is a homeostatic chemokine that is produced by 
endothelial cells of multiple organs including the bone marrow, lung, liver, brain, 
kidney, and heart (73).    
The CXCL12/CXCR4 signaling axis plays a critical role in the retention 
and homing of hematopoietic stem cells (HSCs) in the bone marrow, as well as 
chemotaxis of numerous cell types (74).  Additionally, the CXCL12/CXCR4 axis 
plays a role in other physiologic processes like immune surveillance, HIV-1 
infection, tissue homeostasis, embryogenesis, tumor growth, and metastasis (8, 
75-81).  A number of signaling pathways are activated upon CXCL12 binding to 
CXCR4. These signaling pathways regulate intracellular calcium flux, 
transcription, proliferation, survival, and chemotaxis (summarized in Figure 1.4) 
(62).  Given the role of this axis in many diverse cellular processes, it is 
unsurprising that CXCR4 and CXCL12 knockout mice are embryonic lethal (82, 
83).  These mice exhibit defects in hematopoiesis, heart development, and brain 
development.  
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Figure 1.4. CXCL12/CXCR4 signaling pathways. Upon binding of CXCL12 to CXCR4, a variety of downstream 
signaling pathways are activated leading to several biological processes.  This figure was adapted from (62). 
 
The CXCL12/CXCR4 signaling axis in cancer 
CXCR4 is the most commonly expressed chemokine receptor in human 
cancers, and growing research provides evidence that high CXCR4 expression is 
associated with metastatic disease and poor outcome in over 20 human cancers, 
including breast cancer (84), pancreatic cancer (85), prostate cancer (86), 
leukemia (87), melanoma (88), rhabdomyosarcoma (89-91), neuroblastoma (92), 
and osteosarcoma (93, 94). Specifically in breast cancer, the expression of 
CXCR4 is a key signature of metastatic cells, and early extravasation of liver and 
colon cancer cells is regulated by CXCR4 (84, 95).  In addition to the role of 
CXCR4 in metastasis, there is evidence that CXCR4 contributes to tumor growth 
(96). Interestingly, the sites in which CXCL12 are highly expressed—the lungs, 
bone, bone marrow, liver, lymph nodes, and brain—are all common metastatic 
sites in human malignancies (97).  Notably, the most common metastatic sites in 
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Ewing sarcoma patients are the lung, bone, and bone marrow (98).  These 
findings alone support the hypothesis that CXCR4 may play a critical role in the 
metastasis of Ewing sarcoma. In further support of this, increased expression of 
CXCR4 transcript was recently found to be associated with metastatic disease in 
both Ewing sarcoma derived cell lines and primary tumors (12). Taken together, 
these clinical and experimental observations implicate CXCR4 as a potential key 
mediator of Ewing sarcoma metastasis. 
 
Targeting CXCR4 
Disrupting the CXCL12/CXCR4 signaling axis has received a great deal of 
therapeutic interest.  The molecule, 1,1'-[1,4-phenylenebis(methylene)]-bis-1,4, 
8,11-tetraazacyclotetradecane octahydrochloride dihydrate, also referred to as 
Plerixafor or AMD3100, was first discovered as a potential HIV-1 inhibitor by 
means of inhibiting CXCR4 (99, 100). Plerixafor consists of two cyclam rings 
linked by a 1,4-phenylenebis (methylene) linker (Figure 1.5).  AMD3100 is a 
potent and selective CXCR4 inhibitor and works by preventing the binding and 
function of CXCL12.  Specifically, the protonated cyclam rings of AMD3100 
interact with carboxylate groups in the ligand-binding crevice of CXCR4 (101). It 
has been demonstrated that AMD3100 does not bind any other relevant 
chemokine receptors, confirming the CXCR4 specificity (99).  
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Figure 1.5. Structure of AMD3100. Structure of 1,1'-[1,4-phenylenebis(methylene)]-bis-1,4, 8,11-
tetraazacyclotetradecane. Adapted from (99). 
 
Due to cardiac toxicities, solubility issues, and limited bioavailability, 
Plerixafor was not further developed as an HIV-1 inhibitor (102, 103). Despite 
these limitations, Plerixafor is an FDA approved compound used for stem cell 
mobilization. Specifically, it is approved in combination with G-CSF (granulocyte-
colony stimulation factor) for the mobilization of HSCs for autologous 
transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma 
(104, 105).  Given the abundant evidence for CXCR4 in the pathogenesis of 
many cancers, there has been a great deal of interest in continuing the 
development of novel CXCR4 antagonists as potential cancer therapeutics.  
 
CXCR4 regulation 
To further understand the role of CXCR4 in cancer it is necessary to 
understand the precise mechanisms that regulate CXCR4.  Thus far, there is 
abundant work in the literature describing the regulation of CXCR4 protein 
expression as well as the regulation of CXCR4 signaling. CXCR4 protein 
expression is regulated by several co-translational modifications including 
glycosylation and tyrosine sulfation (106).  Additionally, three processes that 
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regulate GPCR signaling—desensitization, internalization, and degradation—
have been shown to regulate CXCR4 signaling (106).   
Despite the biological significance of CXCR4, little is known about the 
transcriptional regulation of CXCR4.  There is some evidence suggesting that 
CXCR4 transcription is dynamically regulated in response to stimuli.  Cytokines 
(e.g. TGF-1β, IL-2, and IL-10) and growth factors (e.g. bFGF, VEGF, and EGF) 
have been shown to upregulate CXCR4 expression, while some inflammatory 
cytokines have been shown to downregulate CXCR4 (e.g. TNF-α and INF-γ) 
(106-111).  This upregulation is accompanied by an increase in migratory and 
invasive potential. The precise mechanism by which these factors upregulate 
CXCR4 remains unknown; however, given that the CXCR4 locus is rarely 
mutated in cancer, it suggests that overexpression is not genetically determined.  
Therefore, the potential role of epigenetic mechanisms of CXCR4 gene 
regulation was investigated in this thesis. 
 
Epigenetics 
Traditionally, it was thought that the sole underlying cause of cancer is the 
accumulation of genetic mutations (112).  These genetic mutations occur in 
tumor suppressor genes or oncogenes resulting in loss of function or gain of 
function, respectively. Recently there has been a paradigm shift, with new 
evidence demonstrating that in addition to genetic mutations, epigenetics play a 
critical role in cancer.  Epigenetics refers to heritable alterations in gene function 
and gene expression that occur in the absence of changes to the underlying DNA 
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sequence (113-115).  Epigenetic regulation of gene expression occurs via three 
main processes: chromatin remodeling, DNA methylation, and histone 
modifications (summarized in Figure 1.6) (116). 
 
Figure 1.6. Three epigenetic processes that regulate gene expression.  A.  Chromatin remodeling alters nucleosome 
positioning to allow or disallow transcriptional machinery access to the DNA. This remodeling is mediated by SWI/SNF, 
ISWI, NuRD/Mi-2/CHD, INO80 and SWR1 family members. B. DNA methylation is the addition of a methyl group to the 
fifth position of cytosine. This process is carried out by DNMTs. C. Histone modifications are the post-translational 
modifications that occur on the N-terminal tails of histone.  Modifications include acetylation, methylation, phosphorylation 
and ubiquitination. Images are adapted from (117) in A, (118) in B and (119) in C.  
 
Chromatin remodeling 
Alterations in chromatin structure influence the accessibility of 
transcriptional machinery to the condensed genomic DNA.  These alterations are 
controlled by ATP-dependent remodeling complexes that are termed chromatin 
remodelers (120).  Chromatin remodelers all contain a highly conserved ATPase 
subunit, and use energy generated from ATP hydrolysis to reposition 
nucleosomes (move, destabilize, eject, or restructure) (121).  Through their 
effects on nucleosome positioning, these complexes ultimately serve to both 
activate and repress gene expression.  There are five described families of 
chromatin remodeling complexes: SWI/SNF, ISWI, NuRD/Mi-2/CHD, INO80, and 
SWR1 (122) (Figure 1.6A).  The SWI-SNF complex has recently emerged as a 
A            B                   C 
DNA methylation Histone modifications 
SWI/SNF 
ISWI 
NuRD/Mi-2/CHD 
INO80 
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Chromatin remodeling 
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tumor suppressor in some cancers with a high frequency of inactivating 
mutations, close to that of p53 (123).  Ultimately, chromatin remodeling is tightly 
linked to both DNA methylation and histone modifications and the interactions 
between the three processes critically regulate gene expression (124). 
 
DNA methylation 
DNA methylation is an epigenetic modification in which cytosines are 
methylated at the fifth position and subsequently converted to 5-methylcytosines 
by DNA methyltransferases (DNMTs) (Figure 1.6B) (118).  In mammalian 
systems, there are three major DNMTs: DNMT1, DNMT3a and DNMT3b that are 
further classified as either de novo or maintenance DNMTs (125, 126).  De novo 
methyltransferases modify unmethylated DNA, while maintenance DNMTs bind 
to hemi-methylated DNA and add a methyl group to the cytosine of the newly 
synthesized strand.  DNMT1 is the most abundant DNMT and is responsible for 
maintenance methylation throughout life (127). DNMT3a and DNMT3b are de 
novo DNMTs and play critical roles in development (128).  A fourth DNMT, 
DNMT2, has been discovered but has no transmethylase activity (127, 129).  GC 
rich genomic sequences are preferentially targeted for DNA methylation resulting 
in gene silencing.  This silencing commonly occurs through the hypermethylation 
of promoter sequences.  Methylation of promoter regions impedes the binding of 
transcriptional machinery to initiate transcription, and further compacts the 
chromatin through binding of methyl CpG-binding domain proteins (MBD) (130, 
131).  DNA methylation regulates many cellular processes including 
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development, chromosome instability, genomic imprinting, and X-chromosome 
inactivation (XCI) (132-135).  Traditionally DNA methylation has been viewed as 
an irreversible mark; however, recent studies have discovered that TET family 
proteins have the ability to demethylate DNA by converting the 5’-methylcytosine 
to 5’-hydroxymethylcytosine (136). 
DNA methylation has been heavily implicated in cancer, most commonly 
through silencing of critical tumor suppressor genes (137, 138). There is 
evidence, however, that DNA hypomethylation plays a role in the regulation of 
tumor-promoting genes (139, 140). It has been reported that DNA methylation 
regulates CXCR4 and CXCL12 in breast cancer and melanoma. In breast 
cancer, patients with tumors in which CXCR4 was unmethylated had a poorer 
prognosis than patients with tumors in which CXCR4 was methylated (141).  In 
colon cancer, it has been shown that CXCL12 is hypermethylated in the colon 
epithelium, which promotes tumor metastasis (142). The methylation of promoter 
CpG islands is a rare event in normal cells as compared to tumor cells; thus the 
development of tumor-specific DNA methylation inhibitors has been of great 
therapeutic interest (138). Azacitidine and its derivatives have been used to 
inhibit DNA methylation resulting in restored gene expression of aberrantly 
silenced genes (143).  These inhibitors have shown anti-tumor effects both in 
vitro and in vivo and are approved in the clinic for the treatment of high-risk 
myelodysplastic syndrome (MDS)(144).  
 
Histone modifications 
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DNA is wrapped around histone cores H2A, H2B, H3 and H4 in order to 
compact DNA. Two of each of the histone cores come together to form an 
octomeric nucleosome composed of a central H3 and H4 tetramer, and two 
flanking H2A-H2B dimers.  This nucleosome core has approximately 147 base 
pairs of DNA wrapped in a 1.67 left-handed superhelical turn (145).  In addition to 
the four main histone cores, there is an H1/H5 linker histone, which binds to the 
regions between the nucleosomes and helps maintain chromatin structure (146).  
The main histone cores (H2A, H2B, H3, and H4) have histone tails that come out 
of the nucleosome, which can be covalently modified (147). Post-translational 
modifications of the N-terminal tails such as acetylation, methylation, 
phosphorylation and ubiquitination as well as others, play a critical role in 
regulating chromatin state and altering DNA accessibility (148-150) (Figure 
1.6C). 
The most common and best-studied histone modifications are the 
acetylation and methylation of lysine residues on histone H3 and H4, which are 
associated with either transcriptional activation or repression.  Lysine residues 
can be mono-, di- and tri-methylated, each of which confers different functions.  
There are three classes of epigenetic regulators that carry out the regulation of 
the post-translational histone modifications: epigenetic readers recognize the 
histone marks, epigenetic writers lay down the histone marks, and epigenetic 
erasers erase the histone marks (151). Histone acetyltransferases (HATs) (e.g. 
CBP/p300) are the writers for the acetylation mark and histone deacetylases 
(HDACs) (e.g HDAC1-3) erase the mark (152). The writers for methylation are 
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histone methyltransferases (HMTs) and the histone demethylases (e.g LSD1, 
JMJD1A, and JMJD2C) erase the methyl marks (153-155).  
The trithorax group (TrxG) and the polycomb group (PcG) proteins are 
responsible for the opposing actions of gene activation and gene repression 
(156). Functioning within two multi-protein complexes (PRC1 and PRC2) the PcG 
proteins mediate transcriptional silencing (157).  This silencing is specifically 
mediated through the PRC2 complex by the methyltransferase, enhancer of 
zeste homolog 2 (EZH2).  EZH2 has the ability to mono-, di-, and tri-methylate 
H3K27 (H3K27me1/2/3).  Silencing is also mediated through the PRC1 complex 
which mono-ubiquitinates histone H2A on lysine 119 (H2AK119Ub1) (158, 159).  
Transcriptional activation occurs through the methylation or acetylation of lysine 
residues in histone H3 and histone H4.   The trimethylation of lysine residue 4 on 
histone H3 (H3K4me3) is specifically mediated by the TrxG proteins (160).  The 
enzymes responsible for catalyzing this mark include SET1A, SET1B, and mixed 
lineage leukemia (MLL) proteins 1-4 (161). 
This opposition plays an extremely critical role in development, with many 
promoters in human embryonic stem cells (hESCs) exhibiting both TrxG and PcG 
marks—a bivalent chromatin state. Bivalency is defined as the simultaneous 
presence of the repressive, H3K27me3 mark and the activating, H3K4me3 mark.  
Genes that are in this bivalent state are considered to be in a repressed “off” 
state, but are poised and ready for activation in response to development and 
microenvironment cues (162). In response to these cues, the bivalent domains 
can resolve into either active domains characterized by the H3K4me3 mark, or 
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repressed domains characterized by the H3K27me3 mark, resulting in gene 
activation or gene silencing, respectively. One example of this occurs in 
colorectal tumors in which the loss of the H3K27me3 mark from bivalent 
promoters results in the activation of cancer-promoting genes (163).  
Furthermore, it has been demonstrated that there is a link between the genes 
that are bivalent in hESCs and genes that are deregulated in cancer. In cancer, 
many of these bivalent promoters are targeted for DNA methylation, resulting in 
gene silencing and loss of dynamic plasticity (164, 165). 
In addition to promoter regulation by histone modifications, enhancers are 
also regulated by histone modifications. It is estimated that there are hundreds to 
thousands of enhancers in the genome. Enhancers are short (50-1500 bp), cis-
acting DNA sequences that function to increase gene transcription.  Enhancers 
can reside upstream or downstream of the genes they act on.  While there is no 
single mark that characterizes enhancers, genome-wide mapping of histone 
modifications has demonstrated that the monomethylation of histone H3 on 
lysine 4 (H3K4me1) and the acetylation of histone H3 of lysine 27 (H3K27ac) are 
marks of active enhancers (166-168). In addition to these histone marks, it has 
been shown that p300 binding sites reside at enhancers (169). Active enhancers 
that are bound by transcriptional coactivators, such as Mediator, are termed 
super-enhancers (170). In cancer, the acquisition of super-enhancers at key 
oncogenic drivers is a frequent tumorigenic mechanism (171).  Given the critical 
role that enhancers and super-enhancers play in cancer progression, therapeutic 
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strategies have been developed to target enhancer activity; most notable BET 
bromodomain inhibitors such as JQ1 are showing promise (172).   
Developmental programs are under tight epigenetic regulation and cancer 
can be considered a developmental disease. Taking these two together, it is no 
surprise that the hijacking of these epigenetically controlled developmental 
programs is a key feature of human malignancies.  Many human malignancies 
have aberrant expression or mutations in critical components of both the PcG 
and TrxG complexes. In many cancers, including Ewing sarcoma, BMI-1 and 
EZH2, both components of PRC1 and PRC2, respectively, are aberrantly 
overexpressed (173).  The MLL family of proteins are histone 
methyltransferases, responsible for regulating gene expression and are 
frequently aberrant in several human tumors.  For example, MLL1 is commonly 
rearranged in leukemia and MLL2 and MML3 are mutations occur in leukemia 
(174). Given the deregulation of many epigenetic processes in cancer, it is no 
surprise that there is a great deal of interest in targeting these epigenetic 
mechanisms as means of therapy.  
 
Thesis Summary 
The overall aim of this thesis is to elucidate the contribution of CXCR4 to 
Ewing sarcoma pathogenesis, in particular tumor metastasis.  In Chapter Two, I 
describe our investigations into the expression pattern of CXCR4 in Ewing 
sarcoma cell lines and primary tumor samples, which demonstrated 
heterogeneous expression.  Interestingly, we determined that the expression of 
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CXCR4 was highly dynamic and responsive to microenvironmental cues such as 
serum deprivation, hypoxia, and growth constraints, all of which are factors seen 
in a growing tumor.  Functionally, we demonstrated that CXCR4-positive cells are 
migratory and invasive in a CXCR4-dependent manner (to a CXCL12 gradient), 
and that the CXCR4 antagonist, AMD3100, impeded these phenotypes.  In 
Chapter Three, I detail our investigations to determine the molecular 
mechanisms that underlie dynamic regulation of CXCR4 in response to the 
microenvironmental cues discussed in Chapter Two.  We focused our efforts on 
evaluating epigenetic regulation of the CXCR4 locus at both the promoter region 
and at an upstream enhancer element.  We determined that the CXCR4 
promoter resides in a bivalent state in Ewing sarcoma cells and that in response 
to external cues (serum deprivation, hypoxia, and EZH2 inhibition) the 
H3K27me3 mark is lost, resulting in an increase in CXCR4 expression.  
Furthermore, we determined that an enhancer upstream of CXCR4 contributes to 
the regulation of CXCR4. Specifically, the enhancer antagonist, JQ1, inhibits 
CXCR4- to CXCR4+ cell state transitions in response to stress. Together the 
results of the studies detailed in these two chapters demonstrate that epigenetic 
regulation of the CXCR4 locus in response to microenvironmental cues allows 
Ewing sarcoma cells to adopt a more migratory and invasive phenotype.  In 
Chapter Four, I present tools and techniques that we have developed to further 
study the role of CXCR4 in Ewing sarcoma metastasis and disease progression 
in future studies.  To assess the contribution of CXCR4 to the metastatic 
cascade, we optimized a mouse model of spontaneous metastasis that can be 
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used to address mechanistic questions regarding the contribution of CXCR4 to 
disease progression in vivo.  Additionally, we are generating CXCR4 knockout 
cell lines to definitively study the contribution of CXCR4 to biological processes, 
including but not limited to proliferation, migration, invasion, and metastasis.  
Finally, we are developing a CXCR4-GFP knock-in system that will allow us to 
track the plastic and dynamic nature of CXCR4 on a single cell basis in both in 
vitro and in vivo systems. 
The final chapter of this thesis, Chapter Five, discusses the future 
implications of this work.  Specifically, it focuses on extending these findings to 
other tumor types as well as the rationale for the development of novel CXCR4 
antagonists as potential metastasis prevention agents. Because CXCR4 has 
been implicated in the metastasis of many cancers and metastasis is the leading 
cause of death in cancer patients, targeting the CXCL12/CXCR4 signaling axis 
could be a promising avenue for cancer treatment.  
I would like to acknowledge our collaborators, as this thesis would not 
have been possible without their contributions. The primary Ewing sarcoma 
samples and supporting clinical data shown in Figure 2.1 were kindly provided by 
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CHAPTER TWO 
 
STRESS-INDUCED CXCR4 PROMOTES MIGRATION AND INVASION OF 
EWING SARCOMA2 
 
ABSTRACT 	  
Ewing sarcoma is the second most common bone cancer in pediatric 
patients. Although the primary cause of death in Ewing sarcoma is metastasis, 
the mechanism underlying tumor spread needs to be elucidated. To this end, the 
role of the CXCR4/SDF-1a chemokine axis as a mediator of Ewing sarcoma 
metastasis was investigated. CXCR4 expression status was measured in primary 
tumor specimens by immunohistochemical staining and in multiple cell lines by 
quantitative reverse transcriptase PCR and flow cytometry. Migration and 
invasion of CXCR4-positive Ewing sarcoma cells toward CXCL12/SDF-1a were 
also determined. Interestingly, while CXCR4 status was disparate among Ewing 
sarcoma cells, ranging from absent to high-level expression, its expression was 
found to be highly dynamic and responsive to changes in the microenvironment. 
In particular, upregulation of CXCR4 occurred in cells that were subjected to 
growth factor deprivation, hypoxia, and space constraints. This upregulation of 	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sarcoma.” Molecular Cancer Research, 6: 953-64. doi: 10.1158/1541-7786.MCR-
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CXCR4 was rapidly reversed upon removal of the offending cellular stress 
conditions. Functionally, CXCR4-positive cells migrated and invaded toward an 
SDF-1a gradient and these aggressive properties were impeded by both the 
CXCR4 small-molecule inhibitor AMD3100, and by knockdown of CXCR4. In 
addition, CXCR4-dependent migration and invasion were inhibited by small-
molecule inhibitors of Cdc42 and Rac1, mechanistically implicating these Rho-
GTPases as downstream mediators of the CXCR4-dependent phenotype. 
 
INTRODUCTION 
 
Ewing sarcoma is an aggressive bone and soft tissue malignancy that primarily 
affects children and young adults (1). Over the past several decades, overall 
survival has improved dramatically for patients who present with localized 
disease. Multiagent systemic chemotherapy and aggressive local control 
measures have led to 5-year event-free survival rates of 70% to 80% in these 
patients (1, 2). However, for the approximately 25% of patients who present with 
metastatic disease, the outcome is significantly worse. Event-free survival for 
these patients remains less than 25%, and intensification of chemotherapeutic 
regimens has failed to improve outcome (1). In addition, up to a third of patients 
who present with localized disease will relapse at distant sites following an initial 
clinical remission and outcomes for these patients are equally dismal. Innovative 
approaches to therapy and improved understanding of the metastatic process 
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are needed to improve outcomes for patients with primary and relapsed 
metastatic Ewing sarcoma.  
Despite its clinical importance, the biologic mechanisms underlying Ewing 
sarcoma metastasis remain largely unknown. Chemokine receptors are seven-
transmembrane, G-protein–coupled cell surface proteins that are defined by their 
ability to induce chemotaxis through the binding of small chemoattractant 
cytokines or chemokines (3). Chemokine (C-X-C motif) receptor 4 (CXCR4) is 
the most commonly expressed chemokine receptor in human cancer, and 
increased expression of the CXCR4-encoding transcript was recently found to be 
associated with metastatic disease in Ewing sarcoma–derived cell lines and 
tumors (4). Significantly, high CXCR4 expression has also been associated with 
metastatic disease and poor outcome in many other human cancers of both 
epithelial and nonepithelial origin (3, 5), including breast cancer (6), pancreatic 
cancer (7), leukemia (8), rhabdomyosarcoma (9-11), and osteosarcoma (12-14). 
Interestingly, the ligand for CXCR4, CXCL12 (SDF-1α), is highly expressed in 
common sites of Ewing sarcoma metastasis, including lung, bone, and bone 
marrow, further implicating the potential role of this axis in mediating the distant 
spread of primary tumor cells.  
In this study, we evaluated the expression characteristics of CXCR4 in 
Ewing sarcoma primary tumors and cell lines, and specifically addressed whether 
the CXCR4/SDF-1α axis promotes tumor cell migration and invasion. Our 
findings demonstrate that expression of CXCR4 is both highly variable in Ewing 
sarcoma and highly dynamic, being reversibly induced in response to 
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microenvironmental stresses, including growth factor deprivation, hypoxia, and 
space constraints. Moreover, our studies confirm that Ewing sarcoma cells that 
express high levels of CXCR4 display increased chemotactic migration and 
invasion, which is mediated, at least in part by activation of the Rho-GTPases, 
Rac1, and Cdc42. Importantly, inhibition of the CXCR4/SDF-1α axis inhibits the 
aggressive cellular phenotype, thus revealing the potential contribution of CXCR4 
signaling to Ewing sarcoma metastasis. 
 
EXPERIMENTAL PROCEDURES 
 
Cell culture 
Ewing sarcoma cell lines were kindly provided by Dr. Timothy Triche 
Children's Hospital Los Angeles (CHLA, Los Angeles, CA) and the Children's 
Oncology Group (COG) cell bank (www.cogcell.org) and identities confirmed by 
short tandem repeat profiling (courtesy of Dr. Patrick Reynolds, Texas Tech 
University, Lubbock, TX). Cells were maintained in RPMI-1640 media (Gibco) 
supplemented with 10% FBS (Atlas Biologicals, Inc.) and 6 mmol/L l-glutamine 
(Life Technologies) in an incubator at 37°C in 5% CO2. For CHLA-25 studies, 
plates were coated with 0.2% gelatin before cell seeding. For serum-starved 
conditions, cells were cultured in the same conditions without the addition of 
FBS. For hypoxia studies, cells were incubated in 1% O2 in an xVivo system 
(Biospherix) at 37°C and 5% CO2. For growth constraint conditions, cells were 
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cultured under standard culture conditions and CXCR4 analyzed when cells 
reached 100% confluence.  
Quantitative real-time PCR and Western blotting 
RNA was isolated from cell lines (RNeasy Mini; Qiagen) and cDNA was 
generated (iScript; Bio-Rad). Quantitative real-time PCR (qRT-PCR) was 
performed using validated Taqman primers (CXCR4, 18S, and B2M; Life 
Technologies). Analysis was performed in triplicate using the LightCycler 480 
System (Roche Applied Science) and average Cp values were normalized 
relative to reference genes (18S and B2M) within each sample using ΔΔ Cp 
method. Levels of phospho-ERK [Cell Signaling; Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (D13.14.4E) XP Rabbit mAb #4370], phospho-Akt [Cell 
Signaling; Phospho-Akt (Ser473) (D9E) XP Rabbit mAb #4060], Akt [Cell 
Signaling; Akt (pan) (C67E7 Rabbit mAb #4691), Erk (Cell Signaling; p44/42 
MAPK (Erk 1/2) #9102], and ACTIN [Abcam; Anti-beta Actin antibody (HRP) 
(ab20272)] were determined in whole cell lysates using standard Western blot 
assays as previously described (15).  
Cell sorting and assessment of Rac1 activation in sorted populations 
Cells were dissociated with Accutase (EMD Millipore Corporation) and 
resuspended in staining media (L-15 media, 0.1% bovine serum albumin, 10 
mmol/L HEPES; Life Technologies), then blocked for 15 minutes at 4°C with 
agitation (in 0.5% FBS; Atlas Biologicals, Inc.). After blocking, human CXCR4 
Alexa Fluor 488 monoclonal antibody (R&D Systems; clone 44717) was added (5 
µL per 1.0 × 106 cells) and incubated for 30 minutes at 4°C with agitation. After 
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two washes, cells were resuspended in staining media and passed through a 
0.40-µm sterile nylon mesh strainer (Thermo Fisher Scientific). Flow cytometry 
analysis was performed using a BD Accuri C6 Flow Cytometer (BD Biosciences). 
Fluorescence-activated cell sorting (FACS) of cells into CXCR4-positive and 
CXCR4-negative fractions (top 10% and bottom 10%) was done using a 
Beckman Coulter MoFlo Astrios (Flow Core, University of Michigan, Ann Arbor, 
MI) with gating determined by analysis of unstained controls.  
For evaluation of Rac1 activation, FACS-sorted TC-32 cells were serum-
starved overnight in the presence or absence of SDF-1α (200 ng/mL; R&D 
Systems). Levels of Rac1 activation were determined using a G-LISA kit 
(Cytoskeleton) according to the manufacturer's instructions.  
Immunohistochemistry 
For tumor immunohistochemistry, formalin-fixed, paraffin-embedded tumor 
microarray slides were deparaffinized, hydrated, epitope retrieved, and stained 
with an antibody against CXCR4 (dilution 1:500; Abcam; AB-2074) as previously 
validated and described (16). Specificity of the antibody was confirmed in our 
hands by immunostaining of cell pellets collected from CXCR4-high, CXCR4-low 
as well as control and CXCR4 knockdown TC-32 cells. Adjacent tumor 
microarray slides were incubated with CD99 (Mouse monoclonal antibody; clone 
12E7; DAKO; Cat # M3601; 1:100) and hematoxylin and eosin to identify tumor 
cells. Sections were scored for the presence of CXCR4 using the Allred schema 
(17). The proportion of tumor cells was assigned a score between 0 and 5, and 
the staining intensity was assigned a score between 0 and 3. These 2 values 
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were added to produce a staining score. Given recent studies describing nuclear 
localization of CXCR4 in some cancers (18, 19), both cytoplasmic and nuclear 
staining were assessed and equally weighted. Nuclear staining of CXCR4 was 
evident in >10% of nuclei in 35% of cases.  
CXCR4 knockdown 
For CXCR4 knockdown studies, cell lines were transduced with pLKO.1 
puro vectors that contained one of two independent short hairpin RNAs targeted 
to CXCR4:shCXCR4–1: 5′-TGGAGGGGATCAGTATATACA-3′ and shCXCR4-2: 
5′-GTTTTCACTCCAGCTAACACA-3′ (Addgene; plasmid 12271 and 12272; ref. 
(20)) or an inert nonsilencing sequence: shNS: 5′-
CAACAAGATGAAGAGCACCAA-3′. Cells were selected in puromycin (2 µg/mL; 
Sigma) for 72 hours before subsequent experiments.  
In vitro migration and invasion 
Real-time cell analysis (RTCA) of cell migration and invasion was 
monitored using a CIM-plate 16 and xCELLigence DP System (Acea Bioscience, 
Inc.). Cells were serum-starved overnight in RPMI-1640 with 0.2% Media Grade 
(K) Probumin (Millipore). Before cell seeding, electrodes were coated with 0.2% 
gelatin and RPMI-1640 containing 0.2% Probumin was placed in the upper 
chamber, and media containing SDF-1α (100 ng/mL; R&D Systems) were added 
to lower chambers. The CIM-plate was allowed to equilibrate for 1 hour in an 
incubator at 37°C in 5% CO2. For migration studies, 1 × 105 cells/well were 
placed in the upper chamber of a CIM-16 plate and then the plate was 
equilibrated for 30 minutes at room temperature. For migration assays done with 
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combination of stresses, cells were serum-starved and placed in either normoxic 
or hypoxic conditions overnight before evaluation of migration. For invasion 
studies, 1 × 105 cells/well were plated in the upper chamber of wells that had 
been previously coated with 5% (v/v) Growth Factor Reduced Matrigel Matrix 
(diluted 1:20 in basal RPMI media; BD BioSciences). Matrigel-coated plates were 
allowed to equilibrate for 4 hours in an incubator at 37°C in 5% CO2 before 
addition of cells. For compound assays, cells were pretreated overnight with 
either 2.5 µg/mL AMD3100 (Sigma-Aldrich), 30 µmol/L Rac1 inhibitor [NSC 
23766 (hydrochloride); Cayman Chemical), or 7 µmol/L Cdc42 inhibitor (ML 141; 
EMD Millipore) and then seeded in CIM-16 plates as above. Parallel migration 
assays were performed with 2 × 105 cells on 0.8 µm cell culture inserts (Thermo 
Fisher Scientific) for 24 hours. After incubation, noninvading cells were removed 
from the upper surface and inserts were stained (Crystal Violet Stain; 0.5% 
crystal violet, 20% methanol) and migratory cells were imaged by light 
microscopy.  
Statistical analysis 
Data are reported as mean ± SEM from three independent experiments, 
and P values were calculated using the Student t test. 
 
RESULTS 
 
CXCR4 expression is highly heterogeneous in Ewing sarcoma 
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Recent studies of gene expression showed that expression of the CXCR4 
transcript varies among Ewing sarcoma cell lines and tumors (4). To determine if 
expression of the CXCR4 protein is equally heterogeneous, we assessed a panel 
of four well-established Ewing sarcoma cell lines. qRT-PCR analyses 
corroborated earlier studies and demonstrated a wide range of CXCR4 
expression (Figure 2.1A). The variability in transcript expression was mirrored by 
flow cytometry studies of protein expression, with relatively low levels of CXCR4 
detected in TC-71 and A673 cells and high-level expression evident in CHLA-25 
and TC-32 cells (Figure 2.1B). Analysis at the level of individual cells showed 
that the variation in CXCR4 signal intensity between the different cell lines was a 
result of different frequencies of CXCR4-positive cells within each culture (Figure 
2.1B). Specifically, in the two low-expressing cell lines, fewer than 5% of cells 
expressed CXCR4. Conversely, 20% to 40% of cells in CHLA-25 and TC-32 
expressed detectable levels of the receptor at the cell surface. In addition, the 
level of expression in CXCR4-positive populations ranged from weak to robust, 
as demonstrated by the continuum of fluorescence intensities displayed by 
CXCR4-positive cells (Figure 2.1C). To evaluate whether this same 
heterogeneity in CXCR4 protein expression exists in primary tumors, we 
evaluated a tissue microarray comprised of 64 Ewing sarcoma samples. 
Sufficient viable tumor was present to score 43 tumor samples from 32 unique 
patients. Consistent with cell line data, CXCR4 staining showed marked 
intertumor variability, ranging from absent (N = 13) to strongly positive in the 
majority of tumor cells (N = 13). The remainder of the samples (N = 17) showed 
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an intermediate staining pattern in which both CXCR4-positive and CXCR4-
negative tumor cells were identified in the same core specimen Figure 2.1D). No 
difference in staining pattern was identified between 28 samples that were 
obtained from primary tumor specimens and 15 that were isolated at the time of 
disease recurrence (Figure 2.1E). The average CXCR4 score was 5.0 in 4 
diagnostic samples that were obtained from patients with metastatic disease and 
3.8 in 17 localized tumor samples. Although this analysis showed a trend to 
increased expression in primary tumors of patients who present with metastatic 
disease, the sample size is inadequate to draw conclusions about associations 
between CXCR4 expression and clinical stage. Thus, like cell lines, CXCR4 
protein expression is highly heterogeneous in Ewing sarcoma tumors, and 
individual cells within the same tumor also vary in CXCR4   expression. 
Figure 2.1. Heterogeneous expression of CXCR4 in Ewing sarcoma. A, qRT-PCR of CXCR4 
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expression in Ewing sarcoma cell lines. Expression was normalized to the housekeeping 18S 
rRNA in each sample. Individual replicates are shown and the horizontal line represents average 
expression of replicate experiments. B, flow cytometry of CXCR4 cell surface expression in Ewing 
sarcoma cell lines. Data are expressed as the percentage of positive cells. Gating was 
determined based on unstained control cells in the same experiment. Individual replicates are 
shown and the horizontal line represents average expression of replicate experiments. C, 
representative dot plots for each of the 4 cell lines are shown, demonstrating the heterogeneity of 
CXCR4 expression both between cell lines and also showing the range of positivity within the 
CXCR4-positive cell in each cell line. D, immunohistochemical (IHC) staining of 43 Ewing 
sarcoma tumor samples showed marked variability ranging from complete absence to robust 
staining in all tumor cells. Representative examples of robust (score 6–8), intermediate (score 2–
5), and negative (score 0) tumors are shown along with the total number of tumors in each 
category. Both CXCR4-positive and -negative tumor cells were evident in intermediate tumors. E, 
summary of IHC scores for 28 primary tumor samples and 15 relapse samples shows no 
difference in CXCR4 expression between the two categories. 
CXCR4 expression is dynamic and induced in response to growth factor 
deprivation 
Tumor cell heterogeneity is a key factor that contributes to drug resistance 
and tumor progression. We observed significant interexperiment heterogeneity in 
CXCR4 expression in our in vitro studies of Ewing sarcoma cell lines (Figure 
2.1A and B). In particular, we noted that the relative proportion of CXCR4-
positive cells varied substantially between replicate experiments, particularly in 
the two high-expressing cell lines. This observation, together with the highly 
variable nature of expression in tumor samples, led us to hypothesize that 
expression of CXCR4 may be dynamic in Ewing sarcoma and subject to 
regulation in response to changes in the local microenvironment. To begin to 
address this possibility, we tested whether the variability in expression might be a 
consequence of the relative availability of growth factors. To achieve this, we 
measured CXCR4 expression in cells that had been deprived of serum. As 
shown, serum deprivation led to an increased frequency of CXCR4-positive cells 
in three of the four cell lines (Figure 2.2A). Only TC-71 cells remained unchanged 
with fewer than 2% of cells expressing CXCR4 in both serum-rich and serum-
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deprived conditions. To determine if the upregulation of CXCR4 protein 
expression was a consequence of increased CXCR4 transcription, we compared 
mRNA levels in the two conditions. Consistent with transcriptional upregulation, 
CXCR4 mRNA levels increased in all four cell lines following serum deprivation 
(Figure 2.2B). In addition, the degree of transcriptional induction corresponded to 
that of increased protein expression. TC-71 showed the least and TC-32 cells 
showed the most robust upregulation of transcript Figure 2.2B). We next 
evaluated whether restoration of growth factor availability would reverse the 
induction of CXCR4. To achieve this, serum was added to the media of cells that 
had been starved for 24 hours. Following the addition of serum, rapid 
downregulation of CXCR4 expression was observed with levels being restored to 
baseline within 24 hours (Figure 2.2C).  
Next, we addressed whether the reversible changes in CXCR4 expression 
seen in heterogeneous cell populations reflected dynamic regulation at the level 
of individual cells. TC-32 cells were FACS-sorted into pure populations of 
CXCR4-positive and CXCR4-negative cells, and then monitored over 3 weeks in 
ambient culture conditions to determine if positive cells would become negative 
and vice versa. Consistent with dynamic and bidirectional regulation of CXCR4, 
both populations of FACS-sorted TC-32 cells gradually reverted to their basal 
pattern of CXCR4 expression (Figure 2.2D). Specifically, the initial CXCR4-
positive population generated CXCR4-negative cells and the initial CXCR4-
negative population generated CXCR4-positive cells with both cultures 
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reestablishing the baseline equilibrium state of approximately 30% to 40% 
CXCR4-positive cells within 3 weeks.  
 
 
Figure 2.2. CXCR4 expression is reversibly induced in response to growth factor 
deprivation. A, surface expression of CXCR4 was determined by flow cytometry as in Figure 2.1 
for Ewing sarcoma cells plated under standard (10% FBS) and serum-deprived (serum-free 
media, SFM) conditions. Exposure of cells to SFM for 24 hours resulted in upregulation of 
CXCR4. Each line and pair of data points represents the data for an independent experiment. B, 
qRT-PCR analysis of CXCR4 expression in Ewing sarcoma cells grown in SFM conditions for 24 
hours. Expression in each sample was normalized to the housekeeping β 2 microglobulin (B2M) 
and expressed as fold change relative to expression in standard 10% FBS conditions. Results are 
shown as mean ± SEM from three independent experiments. C, flow cytometry of CXCR4 
expression in serum-starved Ewing sarcoma cells (SFM) after being returned to standard culture 
conditions (10%) shows reversion of expression to baseline state. Each line and pair of data 
points represents the data for an independent experiment. D, TC32 cells were FACS-sorted into 
CXCR4-high (top 10%) and CXCR4-low (bottom 10%) populations and then both populations 
were maintained in standard culture conditions for 3 weeks. CXCR4 expression was monitored by 
flow cytometry on days 5, 12, 16, and 21 after sorting, revealing reversion over time to baseline 
heterogeneity. Results are shown as mean ± SEM from three independent experiments. 
 
Thus, CXCR4 expression in Ewing sarcoma cells is dynamic and is rapidly 
and reversibly induced in response to growth factor deprivation. Moreover, Ewing 
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sarcoma cells in standard tissue culture transition back and forth between 
CXCR4-negative and CXCR4-positive cell states in response to changes in the 
microenvironment, ultimately maintaining a basal equilibrium state that is specific 
for each cell line and condition.  
CXCR4 is induced in Ewing sarcoma cells that are exposed to 
hypoxia and growth constraints 
Having established that growth factor deprivation leads to induction of 
CXCR4, we next questioned whether other stresses that might be encountered 
by a growing Ewing sarcoma, such as hypoxia and space constraints, would also 
affect CXCR4 expression. CXCR4 is induced by hypoxia-inducible factor 1-α 
(HIF1-α) in mesenchymal stem cells and cancer cells that are exposed to hypoxic 
environments (21, 22). Consistent with these observations, we discovered that 
exposure of Ewing sarcoma cells to hypoxia resulted in an increase in CXCR4 
transcript (Figure 2.3A) and an increased frequency of CXCR4+ cells (Figure 
2.3B). Removal of the hypoxic insult resulted in a return to basal levels within 48 
hours (Figure 2.3B). Interestingly, in direct contrast to growth factor deprivation, 
TC-71 cells were more susceptible to hypoxia-induced changes than were TC-32 
cells, indicating that the inherent plasticity of CXCR4 expression in response to 
different stimuli varies among the different cell lines. Finally, subjecting cells to 
space constraints, by growing them to confluence, also resulted in reproducible 
upregulation of CXCR4 transcript (Figure 2.3C) and protein expression (Figure 
2.3D) that was reversed when cells were returned to subconfluent, log-phase 
growth conditions (Figure 2.3D).  
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Figure 2.3. CXCR4 expression is reversibly induced in response to hypoxia and cell 
confluence. A, qRT-PCR analysis of CXCR4 expression in Ewing sarcoma cells grown in 
hypoxic conditions for 24 hours shows upregulation of the transcript. Gene expression calculated 
in each sample was normalized to the housekeeping β 2 microglobulin (B2M) and expressed as 
fold change in hypoxia relative to expression in normoxia (control). Histograms represent mean 
fold change ± SEM for three independent experiments. B, flow cytometry of CXCR4 expression in 
Ewing sarcoma cells before (21%) and after (1%) exposure to hypoxia for 24 hours shows 
upregulation of CXCR4 expression in hypoxic conditions. The CXCR4-positive cell frequency 
reverted to baseline 48 hours after cells were returned to ambient (21%) conditions. C, qRT-PCR 
analysis of CXCR4 expression in Ewing sarcoma cells grown in log phase, low density (low) 
compared with confluent, high-density (high) conditions for 48 hours. Gene expression calculated 
as in Figure 3A and expressed as mean fold change ± SEM in high-density cells relative to low-
density (control) cells. D, flow cytometry of CXCR4 expression in log-phase (low) and confluent 
(high) conditions shows upregulation of CXCR4 expression that is then reversed when cells are 
returned to low-density growth conditions after 48 hours. For A and C, results are shown as mean 
± SEM from three independent experiments. For B and D, each line and pair of data points 
represents the data for an independent experiment. 
Thus, like growth factor deprivation, exposing Ewing sarcoma cells to 
hypoxia and space constraints also results in upregulation of CXCR4 
transcription and an increased frequency of CXCR4-positive cells. These 
changes are reversed when these microenvironment stresses are removed, 
demonstrating the highly plastic and dynamic nature of CXCR4 regulation in 
Ewing sarcoma cells.  
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CXCR4 promotes Ewing sarcoma cell migration and invasion 
Given its well-established role as a mediator of metastasis in numerous 
other cancers, we next investigated whether CXCR4 might also contribute to an 
invasive phenotype in Ewing sarcoma. First, we assessed whether Ewing 
sarcoma cells demonstrate chemotactic migration toward SDF-1α. As expected, 
given the very low frequency of CXCR4-positive cells, neither TC-71 nor A673 
cells migrated toward SDF-1α (data not shown). In contrast, the CXCR4-high cell 
lines, CHLA-25 and TC-32 both demonstrated substantial and rapid migration 
toward SDF-1α (Figure 2.4A and B). Moreover, exposure of the cells to 
AMD3100, a small-molecule inhibitor of CXCR4, significantly inhibited this 
chemotactic migration (Figure 2.4A and B). To further validate these findings, we 
induced stable knockdown of CXCR4 in both CHLA-25 and TC-32 cell lines using 
two different short hairpin RNA constructs (Figure 2.4C and D). Consistent with 
pharmacologic inhibitor studies, knockdown of CXCR4 significantly impaired the 
migration of both CHLA-25 and TC-32 cells toward SDF-1α (Figure 2.4E and F).  
	   55	  
 
Figure 2.4. CXCR4 promotes chemotactic migration of Ewing sarcoma cells. A and B, 
migration of CHLA-25 (A) and TC32 (B) cells toward SDF-1α (100 ng/mL) was measured using 
real-time cell analysis (xCELLigence CIM-Plate 16) in the presence and absence of the CXCR4 
inhibitor AMD3100. AMD3100 significantly inhibited chemotaxis. C and D, knockdown of CXCR4 
was effectively achieved in CHLA-25 (C) and TC32 cells (D) using lentiviral transduction of 2 
different shRNA sequences directed against CXCR4 (sh1 and sh2). Control cells were 
transduced with an inert nonsilencing shRNA vector (shNS). Successful knockdown was 
confirmed by qRT-PCR (left) and flow cytometry (right). E and F, migration of CHLA-25 (E) and 
TC32 (F) cells toward SDF-1α (100 ng/mL) was inhibited following knockdown of CXCR4. In all 
plots, graphs represent mean ± SEM of three independent experiments with four replicates per 
condition. **, P < 0.01; ***, P < 0.001; and ****, P < 0.0001 as compared with controls. 
Invasion of cancer cells through basement membranes comprised of 
extracellular matrix proteins is a critical step in the metastatic cascade (23). To 
model this process in vitro, we used Matrigel, a gelatinous protein mixture 
mimicking extracellular components found in tumors (24). Both CHLA-25 and TC-
32 cells invaded through the Matrigel layer toward SDF-1α, and invasion was 
abrogated by both AMD3100 (Figure 2.5A and B) and by CXCR4 knockdown 
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(Figure 2.5C and D). In contrast, SDF-1α had no effect on the invasive potential 
of A673 cells (data not shown). Thus, CXCR4-positive Ewing sarcoma cells are 
stimulated to migrate and invade toward SDF-1α, but modulation of the 
CXCR4/SDF-1α axis by pharmacologic or genetic means can profoundly inhibit 
this response. 
 
Figure 2.5. CXCR4 promotes invasion of Ewing sarcoma cells. A and B, invasion of CHLA-25 
(A) and TC32 (B) cells toward SDF-1α (100 ng/mL) through a Matrigel layer was monitored by 
real-time cell assays as in Figure 4. AMD3100 inhibited migration of both cell lines. C and D, 
knockdown of CXCR4, as in Figure 4, resulted in significant inhibition of invasion of CHLA-25 (C) 
and TC32 (D) cells. Graphs represent mean ± SEM of three independent experiments with four 
replicates per condition. **, P < 0.01 and ***, P < 0.001 as compared with controls. 
Rac1 and Cdc42 mediate CXCR4-dependent migration and invasion 
The mechanisms by which the CXCR4/SDF-1α axis contributes to tumor 
growth and metastasis are pleiotropic, and cell type and context dependent (17). 
Activation of the mitogen-activated protein kinase (MAPK) and phosphoinositide 
3-kinase (PI3K) cascades are both observed downstream of CXCR4 activation 
(17). In addition, studies of breast and liver cancer have shown that the small 
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GTPases, Rho, Rac1, and Cdc42 are activated in these tumors following SDF-1α 
engagement of CXCR4, and that Rho-GTPase signaling is, at least in part, 
responsible for mediating the invasive/metastatic phenotype (25, 26). 
Interestingly, recent studies of Ewing sarcoma have also implicated Rac1 as a 
key mediator of tumor metastasis (27). To begin to address the mechanisms by 
which CXCR4 promotes the invasive cellular phenotype in Ewing sarcoma, we 
assessed the effects of SDF-1α treatment on the MAPK and PI3K pathways by 
evaluating phosphorylation of extracellular signal–regulated kinase (ERK) and 
AKT. As shown, SDF-1α treatment for 24 hours, which promoted cell migration 
and invasion, had no significant impact on activation of either kinase in CHLA-25 
or TC32 cells (Figure 2.6A). Next we investigated whether SDF-1α–dependent 
chemotactic migration and invasion were dependent on Rac1 and/or Cdc42. 
Exposure of Ewing sarcoma cells to either NSC 23766 or ML 141, small-
molecule inhibitors of Rac1 and Cdc42, respectively, resulted in significant 
inhibition of both migration (Figure 2.6B-D) and invasion (Figure 2.6E). In 
particular, inhibition of Rac1 nearly completely abrogated the chemotactic 
invasion of CXCR4-positive Ewing sarcoma cells. To determine if Rac1 activation 
is induced by SDF-1α, TC-32 cells were FACS-sorted on the basis of CXCR4 
and Rac1 activity measured in the different populations in the presence or 
absence of SDF-1α. As shown, CXCR4-high cells displayed higher Rac1 activity 
than CXCR4-low cells, even in unstimulated conditions (Figure 2.6F). Exposure 
to SDF-1α potentiated Rac1 activity in both cell populations but activation of 
Rac1 was reproducibly most pronounced in SDF-1α–stimulated CXCR4-high 
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cells. Together, these studies demonstrate that the invasive cellular phenotype 
imparted to CXCR4-positive Ewing sarcoma cells following SDF-1α engagement 
is, at least in part, mediated by downstream activation of Rac1 and Cdc42 Rho-
GTPases, in particular Rac1.  
 
Figure 2.6. CXCR4-mediated chemotaxis is dependent on Rac1 and Cdc42. A, Western blot 
of CHLA-25 and TC32 cells shows no significant induction of either P-ERK (left) or P-AKT (right) 
following 24-hour exposure of serum-starved cells (SFM) to SDF-1α (100 ng/mL). B and C, 
Endpoint analysis of cell migration toward SDF-1α in the presence or absence of Rac1 (NSC 
23766) or Cdc42 (ML141) inhibitors was performed as described in Materials and Methods using 
transwell assays and crystal violet staining. Inhibition of Rac1 and Cdc42 both impeded CXCR4-
dependent cell migration. D and E, pharmacologic inhibition of Rac1 (NSC 23766) and Cdc42 
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(ML141) inhibits CXCR4-dependent migration (D) and invasion (E) of CHLA-25 and TC32 cells. 
Summary histograms show mean ± SEM of three independent experiments with four replicates 
per condition. *, P < 0.05; **, P < 0.01; and ***, P < 0.001 as compared with controls. F, Rac1 
activity was measured in TC32 cells sorted on the basis of CXCR4. Absorbance values are 
normalized to control condition (0% in CXCR4-low) and summary histograms show mean ± SEM 
of two independent sorts with three replicates per condition. *, P < 0.05. 
CXCR4-dependednt migration is increased in Ewing sarcoma cells that are 
exposed to multiple stresses 
Cells in the center of rapidly growing tumors are subjected to a diminished 
blood supply and must simultaneously endure conditions of both growth factor 
and oxygen deprivation. Given our findings that CXCR4 and CXCR4-dependent 
migration are induced by each of these stresses independently, we next 
investigated whether chemotactic migration of Ewing sarcoma cells would be 
further enhanced in cells that were simultaneously exposed to both serum 
starvation and hypoxia. As predicted, migration of serum-starved (and thus 
CXCR4-upregulated) CHLA-25 and TC32 cells toward SDF-1α was increased 
under hypoxic as compared with normoxic conditions (Figure 2.7A). Together, 
these studies suggest an additive role of microenvironmental stresses in 
promoting CXCR4-mediated Ewing sarcoma cell migration.  
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Figure 2.7. Hypothetical model of stress-induced, CXCR4-dependent invasion and 
metastasis. A, migration of CHLA-25 and TC32 cells toward SDF-1α (100 ng/mL) was measured 
using real-time cell analysis (xCELLigence CIM-Plate 16) in normoxic (21% O2) or hypoxic 
conditions (1% O2). Chemotactic migration of each cell line was further increased in hypoxia 
relative to normoxia. Graphs represent mean ± SEM of three independent experiments with four 
replicates per condition. Cell index was normalized to migration in normoxic conditions for each 
cell line. *, P < 0.05 as compared with controls. B, a growing tumor begins to deplete its 
resources, including growth factors and oxygen. Continued tumor growth leads to space 
constraint at the primary site. Upregulation of CXCR4 in response to these microenvironmental 
stresses promotes invasion of Ewing sarcoma cells through basement membranes and 
extracellular matrix and chemotaxis toward SDF-1α–rich secondary sites such as lung and bone 
marrow. 
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In these studies, we have shown that expression of CXCR4 is 
heterogeneous, both in Ewing sarcoma cell lines and primary tumors, and that 
expression is also highly dynamic. In particular, CXCR4 transcript and protein 
expression are reversibly increased when cells are exposed to serum 
deprivation, hypoxia, and confluent growth conditions. All of these stresses are 
encountered by a growing tumor in vivo as it outstrips its blood supply and 
expands to abut surrounding adjacent tissues, resulting in growth factor and 
oxygen deprivation and space constraints. Using both pharmacologic and genetic 
tools, we have also demonstrated that CXCR4-positive Ewing sarcoma cells 
display a highly migratory and invasive chemotactic phenotype when exposed to 
the CXCR4 ligand, SDF-1α/CXLC12. Our finding that Ewing sarcoma cells 
dynamically regulate CXCR4 leads us to propose a new model of Ewing sarcoma 
tumor cell invasion in which local microenvironment-induced cell stress results in 
upregulation of CXCR4, promoting chemotactic migration and invasion of 
CXCR4-positive Ewing sarcoma cells to distant sites of metastasis. In particular, 
this model proposes a mechanistic basis for the preferential metastasis of Ewing 
sarcoma cells to lungs and bone marrow, microenvironments rich in SDF-
1α/CXLC12 (Figure 2.7B).  
Studies of Ewing sarcoma tumors and cell lines have previously identified 
a potential role for the CXCR4/SDF-1α axis in Ewing sarcoma pathogenesis (4, 
16, 28, 29). In particular, interrogation of gene expression databases identified an 
association between high levels of the CXCR4 transcript and metastatic disease 
(4). In addition, concomitant clinical correlative studies in the same study 
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suggested that Ewing sarcoma tumors that express high levels of CXCR4 and a 
related chemokine receptor, CXCR7, which also binds SDF-1α, are associated 
with worse overall survival (4). More recently, an immunohistochemical study of 
30 Ewing sarcoma tumors revealed robust CXCR4 staining in approximately one 
third of cases, and these investigators also reported an association between 
CXCR4 expression and poor outcome, although no correlation with metastatic 
disease was identified (16). In our own study, we also detected robust expression 
of CXCR4 in approximately one third of cases and an absence of CXCR4-
positive cells in another third. However, CXCR4-positive cells were also identified 
in the remaining third of cases, but tumor cells were found to be heterogeneously 
positive. Consistent with the study by Berghuis and colleagues (16), the pattern 
of CXCR4 expression in our tumor cohort did not correlate with the source of the 
tumor sample. Samples from both primary and recurrent lesions showed equally 
heterogeneous expression patterns. Together, these studies confirm the 
heterogeneous nature of CXCR4 protein expression in primary Ewing sarcoma 
tumors and support further investigation of the contribution of CXCR4 signaling to 
Ewing sarcoma progression. Whether or not high-level expression or an 
increased frequency of CXCR4-positive cells at the time of diagnosis portends a 
worse prognosis for patients still requires further investigation. Specifically, given 
the complexities of prognostic biomarker discovery, it is critical that this question 
next be addressed prospectively in a large cohort of equivalently treated patients 
(30). Moreover, given the highly heterogeneous nature of CXCR4 expression, a 
single core-needle biopsy sample may or may not be representative of CXCR4 
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expression in other areas of the tumor. Ideally, multiple cores should be 
assessed when a dynamically regulated and heterogeneous protein like CXCR4 
is being evaluated as a potential prognostic biomarker.  
Berghuis and colleagues identified a role for CXCR4/SDF-1α in promoting 
cell proliferation, rather than metastasis (16). Given the pleiotropic nature and 
cell context-specific response of CXCR4-dependent signaling, it is not surprising 
that different experimental designs have uncovered different results and 
elucidated different functions for the CXCR4/SDF-1α axis in Ewing sarcoma 
pathogenesis. We have shown that exposure of CXCR4-positive Ewing sarcoma 
cells to SDF-1α results in robust induction of chemotaxis, and that both migration 
and invasion are promoted by activation of CXCR4 signaling. In addition, studies 
with small-molecule inhibitors AMD3100, NSC 23766, and ML 141 showed that 
migration and invasion toward SDF-1α are dependent on CXCR4 and its 
downstream effectors, Rac1 and Cdc42, respectively. Interestingly, our studies 
also indicated that the basal activity of Rac1 is higher in CXCR4-positive Ewing 
sarcoma cells than CXCR4-negative cells, even in the absence of ligand and that 
Rac1 was maximally activated by SDF-1α in the CXCR4-positive population. 
Moreover, we have also found that inhibiting Rac1 blocks SDF-1α –independent 
invasion of serum-starved Ewing cells that do not express high levels of CXCR4 
(data not shown). In addition, Rac1 was also recently implicated as a key 
mediator of Ewing sarcoma cell invasion and metastasis downstream of the 
tyrosine kinase receptor ERBB4 (27). Thus, activation of Rac1 is implicated in 
both nonchemotactic and SDF-1α–mediated Ewing sarcoma migration and 
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invasion, downstream of and in parallel to CXCR4-dependent signaling, 
suggesting that this Rho-GTPase may be a critical downstream hub, present at 
the convergence of multiple Ewing sarcoma metastatic pathways.  
The origins of tumor heterogeneity are multifactorial, and contributing 
factors include genetic variation, stochastic processes, different 
microenvironments, and cell plasticity (31). Indeed, dynamic regulation of 
metastasis-inducing genes in response to exogenous cues is a hallmark of 
epithelial cancer cell plasticity, resulting in epithelial–mesenchymal transition 
(EMT), a critical initiating event in the onset of carcinoma metastasis (32). Unlike 
most adult solid tumors, pediatric solid tumors mainly arise from nonepithelial 
tissues, predominantly neural and mesenchymal lineages, thus obviating a role 
for EMT. We have discovered that, like EMT genes in epithelial cancers, CXCR4 
expression in Ewing sarcoma is highly plastic and this phenotypic plasticity 
results in functional changes that can contribute to cell invasion and metastatic 
dissemination. In particular, CXCR4 expression is highly responsive to stresses 
in the local microenvironment, reverting to its basal state when the stressor is 
removed. Consistent with this observation, dynamic regulation of CXCR4 has 
also been observed in neuroblastoma, a neural crest–derived solid tumor (33, 
34), demonstrating that plasticity of CXCR4 is not limited to Ewing sarcoma. 
Interestingly, high levels of CXCR4 have also been identified in tumor- and 
metastasis-initiating cancer stem cell populations (7, 35, 36), suggesting that 
dynamic regulation of CXCR4 may contribute to the dynamic regulation of 
stemness that has been described in highly plastic cancer cell populations (37). 
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We hypothesize that dynamic regulation of CXCR4 in Ewing sarcoma, as well as 
other pediatric solid tumors, contributes to cellular heterogeneity and supports 
the dynamic transition of cells between nonmetastatic and metastatic states. 
Studies are ongoing in our laboratory to determine the precise molecular 
mechanisms that underlie the dynamic regulation of CXCR4 expression and to 
define whether it is under the control of epigenetic, transcriptional, and/or 
posttranscriptional regulatory pathways.  
Current systemic cytotoxic agents have reached the limit of tolerability, 
and novel approaches to treatment, in particular approaches that prevent 
metastatic relapse, are desperately needed for Ewing sarcoma and other 
invasive solid tumors (38). The CXCR4/SDF-1α axis is a well-established 
mediator of tumor metastasis, and it offers a potentially attractive therapeutic 
target for the treatment and prevention of metastatic disease (17). Our current 
work, along with recent studies of other sarcomas and neuroblastoma (9, 10, 14, 
34, 39), suggests that this axis represents a potential target for metastasis 
prevention in Ewing sarcoma as well as other aggressive pediatric tumors and 
should be further investigated in relevant preclinical therapeutic models of these 
cancers. In particular, studies of spontaneous metastasis using orthotopic, 
patient-derived xenograft models will be most informative and should be pursued 
for preclinical studies of CXCR4-targeted therapies. 
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CHAPTER THREE 
 
EPIGENETIC PLASTICITY OF THE CXCR4 LOCUS CONTRIBUTES TO CELL 
STATE TRANSITIONS IN EWING SARCOMA3 
 
ABSTRACT 
 
Tumor heterogeneity and cellular plasticity are means by which tumors 
can evade upfront therapy and progress to metastatic disease.  This diversity is a 
major therapeutic dilemma.  Tumor cell heterogeneity can be mediated by both 
genetic and epigenetic mechanisms, which can be modulated by the tumor 
microenvironment.  We recently reported that expression of CXCR4 is highly 
heterogeneous as well as dynamic and responsive to microenvironmental cues in 
Ewing sarcoma.  In particular, CXCR4 expression is induced in response to 
serum deprivation, hypoxia, and growth constraints.  This expression induction 
leads to the transition of cells from a CXCR4- non-motile to a CXCR4+ highly 
motile state.  In this study, we investigated the potential contribution of epigenetic 
regulation of CXCR4 cell-state transitions in response to changes in the 
microenvironment.  We have demonstrated that the CXCR4 promoter exists in a 	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bivalent state with simultaneous enrichment of both the activating H3K4me3 and 
the repressive H3K27me3 histone marks.  Significantly, exposure of Ewing 
sarcoma cells to serum deprivation or hypoxia resulted in loss of histone mark 
bivalency as evidenced by loss of H3K27me3 with retention of H3K4me3 
modifications.  Finally, we demonstrated that an upstream enhancer also 
contributes to CXCR4 regulation.  In support of this, treatment of Ewing sarcoma 
cells with the enhancer antagonist, JQ1, resulted in marked down regulation of 
CXCR4 expression in ambient conditions. Furthermore, JQ1 treatment blocked 
up-regulation of CXCR4 in response to both serum deprivation and hypoxia.  
Collectively, these data demonstrate a key role for the epigenetic regulation of 
CXCR4, thus highlighting a novel opportunity for the development of innovative 
therapeutic strategies that tackle the complex issue of cellular plasticity and 
tumor heterogeneity in Ewing sarcoma.  
 
OBJECTIVE STATEMENT 
 
In Chapter Two, we demonstrated that in response to stress (serum 
deprivation, hypoxia and growth constraints), Ewing sarcoma cells dynamically 
regulate CXCR4 by transitioning from CXCR4- to CXCR4+ states. Additionally, 
this transition is accompanied by an increase in the migratory and invasive 
potential of Ewing sarcoma cells. Furthermore, CXCR4 heterogeneity is evident 
even between cells within the same tumor or cell culture (1).  We next sought to 
determine the molecular mechanisms that drive the dynamic regulation of 
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CXCR4.  We specifically propose that this dynamic regulation is governed, at 
least in part, by epigenetic plasticity at the CXCR4 gene locus.  Our recent 
findings on the molecular mechanisms regulating CXCR4 plasticity are 
summarized in this chapter. 
 
INTRODUCTION 
 
Thus far, Ewing sarcoma biological studies and clinical trials have largely 
failed to address the inherent heterogeneity and phenotypic plasticity of tumor 
cells.  Tumor heterogeneity contributes to tumor progression and remains a 
major challenge in the treatment and diagnosis of cancer as well as of the 
development of novel cancer therapeutics (2, 3).  Furthermore, both tumor and 
stromal cells can contribute to tumor heterogeneity, which results in phenotypic 
heterogeneity among cells.  This phenotypic heterogeneity can include variability 
in gene expression, motility, and metastatic potential across cells in a tumor (4).  
This heterogeneity can be driven by both intrinsic genetic and epigenetic 
mechanisms as well as by contributions of the tumor microenvironment (3, 5).  
Current evidence suggests that Ewing sarcoma tumors are driven by epigenetic 
mechanisms rather than genetic mechanisms (6).  On average, 33 to 66 genes 
exhibit somatic mutations in any given tumor type (7). Melanoma exhibits far 
more mutations than average with ~200 mutations per tumor and the majority of 
pediatric tumors exhibit far fewer than the average number of mutations (7).  In 
Ewing sarcoma, the EWS-ETS translocation is considered pathognomonic and 
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aside from the occasional STAG2 (15%), CDKN2A (10%) and TP53 (6%) 
mutations, the translocation is the predominant genetic driver (8-10).  This 
suggests that tumor heterogeneity in Ewing sarcoma is driven by factors other 
than strictly genetic mechanisms.  
Cellular plasticity is an adaptive strategy adopted by cancer cells in order 
to survive and undergo disease progression.  This cancer cell plasticity can be 
mediated by microenvironmental signals that modulate reversible epigenetic 
modifications (11).  Epigenetic regulation of chromatin plays a critical role in 
normal development and tissue maintenance (12).  Two of the most prevalent 
protein complexes that modulate chromatin structure are the Polycomb group 
(PcG) and Trithorax group (TrxG) complexes, which regulate thousands of 
genomic loci (13-15). Dysregulation of these protein complexes has been 
implicated in cancer pathogenesis.  PcG and Trx proteins are recruited to the loci 
of developmental genes and act antagonistically by depositing chromatin marks 
that repress (trimethylation of histone H3 on lysine 27: H3K27me3) or activate 
(trimethylation of histone H3 on lysine 4: H3K4me3) gene expression, 
respectively.  In embryonic stem cells, the promoters of many developmental 
genes are maintained in a bivalent state characterized by the simultaneous 
presence of both the H3K4me3 and H3K27me3 marks (16). This bivalent state 
allows for rapid gene activation or repression in response to developmental and 
microenvironmental cues.  In cancer, the regulation of bivalent chromatin 
domains contributes to tumor cell heterogeneity and phenotypic fates (17).  
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In the current study, we have demonstrated that CXCR4 locus is 
epigenetically regulated and that a bivalent promoter allows CXCR4 to be rapidly 
activated in response to stress.  Additionally, we demonstrate that an enhancer 
upstream of CXCR4 contributes to its regulation and that the enhancer 
antagonist, JQ1, can be used to block CXCR4 state transitions.  
 
MATERIALS AND METHODS 
 
Cell culture 
Ewing sarcoma cell lines were cultured in RPMI-1640 media (Gibco, 
Grand Island, NY, USA) supplemented with 10% FBS (Atlas Biologicals, Inc., 
Fort Collins, CO, USA) and 6mM L-glutamine (Life Technologies, Grand Island, 
NY, USA) at 37°C and 5% CO2.  For CHLA-25 cells, prior to cell seeding, plates 
were briefly coated (~5 minutes) with 0.2% Gelatin (Gelatin from bovine skin, 
Type B). For serum starved conditions, cells were cultured in the same 
conditions without the presence of FBS for 24 hours. For hypoxia studies, cells 
were incubated in an xVivo system (Biospherix, Lacona, NY, USA) at 1% O2, 
37°C and 5% CO2 for 48 hours.  For GSK-126 studies, cells were treated with 
either vehicle control (DMSO; D128-500, Fisher Scientific, Waltham, MA) or 
10µM GSK-126 (A-1275, Active Biochem, Maplewood, NJ) daily for 72 hours 
prior to functional studies. For (+)-JQ1 studies, cells were treated with either 
vehicle control (DMSO; D128-500, Fisher Scientific, Waltham, MA), or 1 µM (+)-
JQ1 (11187, Cayman Chemical, Ann Arbor, MI) for 24 hours. 
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Quantitative real-time PCR 
RNA was isolated using the Quick-RNA™ MiniPrep kit (Zymo Research, 
Irvine, CA) and cDNA was generated using iScript (Bio-Rad, Hercules, CA). 
Quantitative real-time PCR was performed using validated CXCR4 and beta-2-
microglobulin (B2M) Taqman assays (Life Technologies, Grand Island, NY).  
Analysis was performed in triplicate using the Lightcycler® 480 System.  Using 
the ΔΔCt method, gene expression was normalized to the reference gene. 
 
Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation was performed according to the methods 
of Gilfillan et al. 2012 (18).  In brief, Ewing sarcoma cells (3.6x105 per IP) were 
digested with Micrococcal nuclease (MNase) (70196Y, Affymetrix, Santa Clara, 
CA) for 5 minutes at 37°C, sonicated for 20 seconds (Qsonica cup horn sonicator 
(Qsonica Sonicators, Newtown, CT, USA)), blocked for 1 hour with Dynabeads 
A+G (10001D and 10003D; Life Technologies, Carlsbad, CA), incubated with 1 
µg of desired antibody overnight, incubated with Dynabeads A+G for 3 hours, 
washed (5 minute wash; 5 x RIPA buffer, 1 x LiCl buffer, 1 x TE buffer), digested 
proteins with Proteinase K for 1 hour at 55°C and purified immunoprecipitated 
DNA according to manufacturer’s instructions (Zymo Genomic DNA Clean & 
Concentrator, D4011).  For ChIP-re-ChIP studies, after the 3 hour incubation with 
Dynabeads A+G, the beads were incubated with dithiothreitol (DTT) (10mM final 
concentration, 15508-013, Life Technologies, Carlsbad, CA) for 30 minutes at 
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37°C.  Chromatin was then incubated with the desired second antibody overnight 
and the protocol continued as above. Primer pairs for the CXCR4 promoter and 
enhancer region are listed in Table 3.1. 
 
 
Table 3.1, Related to Figure 3.1 and Figure 3.6. Primers used for ChIP quantitative genomic 
PCR and ChIP-re-ChIP analysis.  
 
Antibodies 
Antibodies were used for chromatin immunoprecipitation per 
manufacturer’s instructions; H3K4me3 Rabbit anti-Human Polyclonal Antibody 
(49-1005; Life Technologies, Carlsbad, CA), Anti-trimethyl-Histone H3 (Lys27) 
Antibody (07-449; Millipore, Billerica, MA), Anti-Histone H3 (acetyl K27) antibody 
(ab4729; Abcam, Cambridge, MA), Anti-Histone H3 (mono methyl K4) antibody 
(ab8895; Cambridge, MA), normal mouse IgG (sc-2025; Santa Cruz 
Biotechnology, Dallas, TX), Rabbit IgG  (ab37415; Abcam, Cambridge, MA). 
 
Promoter Region 
Primer Forward Reverse Size (bp) 
#3 5'- GGG TGG TCG GTA GTG AGT CC -3' 5'- CAG AGA GAC GCG TTC CTA GC -3' 120 
#5 5'- ACG CCT TCT CTG CAG TTG TG -3' 5'- TTC CAG TGG CTG CAT GTG TC -3' 105 
#6 5'- GGG CTG CGC TCT AAG TTC AA -3' 5'- TAG CAA AGT GAC GCC GAG G -3' 144 
#3_1 5'- GGG ATG TCT TGG AGC GAG TT -3' 5'- AAC AGT CAC CAG GCG CTT AA -3' 122 
#8 5'- TCA CTA GGG TCA GGT GCA GA -3' 5'- TCG CGA ATT GGT TAC CGC TA -3' 131 
GAPDH 5'- TAC TAG CGG TTT TAC GGG CG -3’ 5'- TCG AAC AGG AGG AGC AGA GAG CGA -3' 166 
Enhancer Region 
#1 5'- GGC TAG GAG GTG TGG ATG AA-3' 5'- CCA GAG TTG CCA CAG GAG AT-3' 126 
#2 5'- CCC TTT CTG GGC TTT TTC TT-3' 5'- TTT GTG AAG GTG CCC TAT CC-3' 122 
#3 5'- AAG GCT TTG AAG GCA CTG AA -3' 5'- GAC ATG AGG CAA TGC AAG AC-3' 124 
#4 5'- TGT GGC AGC TGT GAA GAA TC-3' 5'- CTG GGA AGT AGG GCA GTC AG-3' 125 
#5 5'- AGA GGG TAG GAG GGC TGT GT -3' 5'- CCC ACT GCT AGG CTT TTC TG-3' 129 
#6 5'- CAT ATC CCC TGG AGG ACC TT-3' 5'- TTT TCT GCT GTC CCA ACT CC-3' 125 
#8 5'- CAG TAT GAC CAG GGG TTT GC-3’ 5'- TCT GGC AAT GAT TCC TCC TC-3’ 125 
Supplemental Table 1, Related to Figure 1 and Figure 6. Primers used for ChIP quantitative PCR 
analysis. Table of primer pairs used for ChIP-qPCR and ChIP-re-ChIP-qPCR. 
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Cell sorting 
Cell sorting was performed as previously described (1). In brief, cells were 
blocked for 15 minutes at 4˚C with agitation (0.5% FBS), incubated with human 
CXCR4 Alexa Fluor 488 monoclonal antibody (5 µL/ 1.0x106 cells) for 30 minutes 
at 4˚C with agitation, passed through a 0.40 µm sterile nylon mesh strainer and 
sorted into CXCR4negative (bottom 10%) and CXCR4positive (top 10%) on a 
Beckman Coulter MoFlo Astrios. 
 
In vitro migration and invasion 
Migration and invasion assays were performed as previously described 
(1). In brief, 1.0x105 pretreated CHLA-25 or 2.0x105 TC32 cells in RPMI-1640 
media containing 0.2 % Probumin (Millipore, Billerica, MA) were seeded in the 
upper chamber of a CIM-16 plate (Acea Bioscience, Inc., San Diego, CA) and 
media containing SDF-1α (100 ng/mL, R&D Systems) was added to the lower 
chamber.  For the invasion assays, the upper chamber was coated with a layer of 
Matrigel™ (Growth Factor Reduced Matrigel Matrix was diluted 1:20 in media, 
BD Biosciences, San Jose, CA).  Prior to the assay, the electrodes were coated 
with 0.2% gelatin for 30 seconds at room temperature. Migration and invasion 
assays were carried out in an xCELLigence DP system with measurements 
every hour over a period of 12 hours and 36 hours, respectively.  
 
Statistical analysis 
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Data are reported as mean ± SEM from a minimum of three independent 
experiments unless otherwise indicated. P-values were calculated using ratio 
paired t-test unless otherwise indicated.   
 
RESULTS 
 
The CXCR4 promoter is bivalent in Ewing sarcoma cells 
Epigenetic histone modifications play a well-established role in gene 
expression.  Given our findings that CXCR4 mRNA is rapidly and reversibly up 
regulated in response to cellular stresses (1), we sought to assess the role of 
epigenetic mechanisms in regulating CXCR4 plasticity.  Having determined that 
the CXCR4 promoter resides in a bivalent state in human embryonic stem cells 
(Figure 3.1A), we sought to determine if the CXCR4 locus is bivalent in Ewing 
sarcoma cells. We first assessed whether the histone modifications H3K4me3 
and H3K27me3 are present at the CXCR4 locus in Ewing sarcoma cells. Five 
primer sets (#3, #5, #6, #8, and #3_1) were designed for the CXCR4 promoter 
(Figure 3.1B). We performed chromatin immunoprecipitation (ChIP) studies 
followed by quantitative genomic PCR (qPCR) in a panel of Ewing sarcoma cells, 
with the cell lines ranging from low CXCR4 expression to high CXCR4 
expression (Figure 3.1C). We determined that both histone marks (H3K4me3 
and H3K27me3) were present at the CXCR4 locus in cells grown under standard 
culture conditions (unstressed and unsorted) (primer set #8, Figure 3.1D).  
Additional primer sets demonstrated similar results (Figure 3.2).  These results 
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may reflect populations of cells with either H3K4me3 or H3K27me3 marks.  
Therefore, to determine true bivalency, we performed sequential ChIP 
experiments on the same chromatin in TC71, A673, CHLA-25, and TC32 cells.  
These ChIP-re-ChIP studies confirmed that the CXCR4 locus is bivalent in Ewing 
sarcoma (Figure 3.1E).  In HeLa cells, the CXCR4 promoter is characterized by a 
univalent state, with enrichment of only the H3K4me3 mark (ENCODE Database, 
Figure 3.3).  Additionally, HeLa cells have very high expression of CXCR4 with 
nearly 100% of the cells expressing CXCR4 (Figure 3.1F and 3.1G).  We 
confirmed the ENCODE findings with ChIP-qPCR and ChIP-re-ChIP experiments 
demonstrating that HeLa cells are not bivalent and are marked solely with the 
H3K4me3 mark (Figure 3.1H and 3.1I). 
Thus, these data demonstrate that in Ewing sarcoma cells the CXCR4 
promoter exists in a bivalent state and, as such, may be poised ready for 
activation in response to microenvironmental cues. 
	   80	  
 
Figure 3.1.  The CXCR4 promoter resides in a bivalent state in Ewing sarcoma. Gene tracks 
for H3K4me3 and H3K27me3 at the CXCR4 promoter in human embryonic stem cells (hESC) 
assembled from the ENCODE database demonstrate a bivalent state (A). Map of primer pairs 
designed for the CXCR4 promoter region (B). CXCR4 expression was determined in a panel of 
Ewing sarcoma cell lines using qRT-PCR (Low Expression: A4573, TC71, A673; High 
Expression: CHLA-25, TC32) (C).  Chromatin immunoprecipitation (ChIP) followed by quantitative 
PCR (qPCR) was used to assess the presence of the activating mark H3K4me3 and the 
repressive mark H3K27me3 in Ewing sarcoma cell lines (C). Under standard culture conditions, 
the H3K4me3 and H3K27me3 marks were enriched at the CXCR4 promoter in a panel of Ewing 
sarcoma cells (D).  Sequential Chromatin immunoprecipitation (ChIP-re-ChIP) for H3K4me3 
followed by H3K27me3 (K4/K27) and vice versa, H3K27me3 followed by H3K4me3 (K27/K4) was 
performed on TC71, A673, CHLA-25, and TC32 cells confirming that the CXCR4 promoter is 
bivalent as marked by simultaneous presence of both H3K4me3 (activating) and H3K27me3 
(repressive) histone modifications (E).  IgG, K4/K4, and K27/K27 served as controls.  HeLa cells 
express high levels of CXCR4 (F and G).  HeLa cells are not bivalent and are marked solely with 
the H3K4me3 mark (H and I). Data represented as mean ± SEM of three independent 
experiments. 
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Figure 3.2, Related to Figure 3.1. Enrichment of H3K4me3 and H3K27me3 marks at the 
CXCR4 promoter. ChIP-qPCR for the H3K4me3 and H3K27me3 histone modifications and IgG 
control at the CXCR4 promoter in a panel of Ewing sarcoma cell lines under standard culture 
conditions for primer sets #5, #6, #8, #3_1, and negative controls. Data represented as mean ± 
SEM of three independent experiments. 
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Supplemental Figure 1, Related to Figure 1. Enrichment of H3K4me3 and H3K27me3 Marks 
at the CXCR4 Promoter. ChIP-qPCR for the H3K4me3 and H3K27me3 histone modifications and 
IgG control at the CXCR4 promoter in a panel of Ewing sarcoma cell lines under standard culture 
co itions fo  primer sets #5, #6, #8, #3_1, and Negative. Data represented as mean ± SEM of 
three independent experiments. 
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promoter in HeLa Cells.  Gene tracks assembled from the ENCODE database demonstrate that 
the CXCR4 promoter in HeLa cells is marked by the enrichment of H3K4me3 and the absence of 
H3K27me3 histone marks. 
 
Histone marks correlate with CXCR4 expression 
Having demonstrated that CXCR4 expression is heterogeneous in Ewing 
sarcoma cells we wanted to assess whether expression correlated with 
epigenetic marks.  To this end, we analyzed the histone marks at the CXCR4 
promoter in more homogenous populations of cells that had been sorted on the 
basis of CXCR4 expression.  CHLA-25 and TC32 cells were FACS sorted into 
CXCR4negative and CXCR4positive fractions (bottom 10% and top 10%) with gating 
parameters determined by unstained controls (Figure 3.4A and B).  As expected, 
CXCR4 mRNA expression correlated with surface levels of CXCR4 in the two 
populations, with the CXCR4negative population expressing low levels of CXCR4 
and the CXCR4positive population expressing high levels of CXCR4 (Figure 3.4C 
and D).  Consistent with our hypothesis that epigenetic mechanisms contribute to 
the regulation of CXCR4 expression, analyses of histone modifications at the 
CXCR4 promoter demonstrated preferential enrichment of H3K27me3 in the 
CXCR4negative population (Figure 3.4E and F), while the CXCR4positive population 
demonstrated preferential enrichment of the H3K4me3 mark (Figure 3.4G and 
H).  These data indicate that CXCR4 expression levels are inversely correlated 
with the H3K27me3 mark and directly correlated with the H3K4me3 mark at the 
gene promoter. 
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Figure 3.4. Sorting on the basis of CXCR4 correlates with histone marks. CHLA-25 (A) and 
TC32 (B) cells were FACS-sorted into CXCR4negative (bottom 10%) and CXCR4positive (top 10%) 
using the Beckman Coulter MoFlo Astrios. CXCR4 expression by qRT-PCR correlated with 
CXCR4 surface protein expression as determined by flow cytometry (C and D). ChIP experiments 
were performed on both the CXCR4negative and the CXCR4positive populations revealing that in 
sorted CHLA-25 and TC32 cells, CXCR4 expression is inversely correlated with H3K27me3 (E 
and F) and directly correlated with H3K4me3 (G and H) marks (H3K4me3: positive and 
H3K27me3: negative).  Data represented as mean ± SEM of three independent experiments. 
 
Conditions that induce upregulation of CXCR4 in Ewing sarcoma cells also 
induce loss of bivalency at the CXCR4 promoter 
Having demonstrated that the CXCR4 locus is bivalent in Ewing sarcoma 
cells, we next explored if changes in histone modifications occurred in response 
to cellular stress, converting the CXCR4 locus from a bivalent, repressed state to 
a univalent, active state.  We previously demonstrated that in response to serum 
deprived and hypoxic conditions, CXCR4 expression was upregulated, though to 
varying levels across cell lines (1).  We subjected four Ewing sarcoma cell lines 
to serum deprived conditions for 24 hours and then performed ChIP-qPCR for 
the H3K27me3 and H3K4me3 histone marks.  A673 cells robustly upregulated 
CXCR4, CHLA-25 and TC32 moderately upregulated CXCR4, and CXCR4 
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Figure 3. Sorting on the Basis of CXCR4 Correlates with Histone Marks. Representative dot plots for 
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expression in the two populations (CXCR4 Low and CXCR4 High) of CHLA-25 (B) and TC32 (E) correlated 
with CXCR4 surface expression. Normalized ChIP-qPCR data at the CXCR4 promoter in sorted CHLA-25 (C) 
and TC32 cells (F) demonstrated that CXCR4 expression is directly correlated with H3K4me3 and inversely 
correlated with H3K27me3 marks. Data represented as mean ± SEM of three independent experiments.
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expression was unchanged in TC71 cells (Figure 3.5A).  We found that in 
response to serum deprivation, there was a marked reduction in H3K27me3 
enrichment in A673, CHLA-25 and TC32 cells relative to standard culture 
conditions (10%) (Figure 3.5B), however there was no change in the H3K4me3 
enrichment in response to serum-deprived conditions (Figure 3.5C).  TC71 cells, 
which did not upregulate CXCR4, had no change in H3K27me3 enrichment in 
serum-deprived conditions (Figure 3.5B).  These data suggest that loss of the 
H3K27me3 mark at the CXCR4 promoter contributes to upregulation of CXCR4 
in response to serum deprivation. 
Next, Ewing sarcoma cells were subjected to hypoxia for 48 hours.  In 
response to hypoxia, CHLA-25 cells upregulated CXCR4 while CXCR4 
expression was unchanged in A673, TC32, and TC71 cells (Figure 3.5D). In 
CHLA-25 cells, the H3K27me3 mark was lost in response to hypoxic stress, but 
was unchanged in A673, TC32 and TC71 cells (Figure 3.5E).  Additionally, 
H3K4me3 marks were unchanged in response to hypoxic stress (Figure 3.5F). 
These data suggest that Ewing sarcoma cell response to hypoxic stress was 
highly variable across cells lines and only CHLA-25 reproducibly upregulated 
CXCR4 in these conditions.  Collectively, these data demonstrate that the 
bivalent state of the CXCR4 promoter allows Ewing sarcoma cells to rapidly 
switch states from a CXCR4-negative to a CXCR4-positive state.  Further, they 
show that the stimuli that can induce CXCR4 upregulation and loss of bivalency 
are highly cell-context dependent, even among Ewing sarcoma cell lines. 
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Given our findings that the H3K27me3 mark was lost in response to 
microenvironmental stresses, we sought to determine if this was mediated by 
EZH2, the methyltransferase responsible for the H3K27me3 mark.  We took 
advantage of GSK-126, the EZH2 inhibitor that is 1000-fold more selective for 
EZH2 than other histone methyltransferases (19). Ewing sarcoma cells were 
treated with subcytotoxic doses of GSK-126 (10 µM) for 72 hours resulting in 
global loss of H3K27me3 (data not shown).  Interestingly, treatment with GSK-
126 resulted in the upregulation of CXCR4 in A673, TC71, TC32 and CHLA-25 
cells (Figure 3.5G).  Further, this upregulation was accompanied by the 
corresponding loss of the H3K27me3 mark at the CXCR4 promoter (Figure 
3.5H).  As anticipated, there was no effect of GSK-126 on the enrichment of the 
H3K4me3 mark (Figure 3.5I).  These data demonstrate that EZH2 mediates the 
H3K27me3 mark at the CXCR4 locus. 
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Figure 3.5. Ewing sarcoma cells lose the repressive H3K27me3 mark at the CXCR4 
promoter in response to stress. Ewing sarcoma cells were cultured in standard conditions for 
24 hours.  Cells were then exposed to different micro-environmental stresses: serum free media 
(SFM) for 24 hours, or hypoxia (1% O2) for 48 hours, or GSK-126 (10 µM) for 72 hours prior to 
performing ChIP experiments.  Expression of CXCR4 was determined using qRT-PCR under 
non-stressed and stressed conditions. In response to serum deprivation, A673, CHLA-25, and 
TC32 cells lost the H3K27me3 (B), which resulted in CXCR4 upregulation (A).  TC71 cells did not 
upregulate CXCR4 (A) and there was no change in H3K27me3 enrichment (B). There was no 
change in H3K4me3 enrichment after serum deprivation (C).  Additionally, under conditions of 
hypoxia CHLA-25 cells upregulated CXCR4 (D) and the H3K27me3 mark was lost (E) whereas 
TC71, A673, and TC32 cells did not upregulate CXCR4 (D) and there was no change in 
H3K27me3 enrichment (E).   As expected, there was no change in H3K4me3 enrichment in 
response to hypoxic stress (F).  Treatment of Ewing sarcoma cells with subcytotoxic doses of the 
EZH2 inhibitor, GSK-126, resulted in an increase in CXCR4 expression (G).  This increase in 
CXCR4 expression was accompanied by a substantial loss in H3K27me3 enrichment (H).  
Additionally, there was no difference in H3K4me3 enrichment after treatment with GSK-126.  
Results shown as mean ± SEM (n=3).  
 
Our current findings demonstrate that the CXCR4 locus resides in a 
bivalent state and that exposure of Ewing sarcoma cells to serum deprivation or 
hypoxic stress increases CXCR4 expression resulting in a population of cells that 
possess an increased tumorigenic potential. This increase in CXCR4 is driven by 
the loss of H3K27me3, which is mediated by EZH2. 
CXCR4 sorted cells upregulate CXCR4 in response to serum deprivation 
The above data show that CXCR4 expression correlates directly with 
H3K4me3 and inversely with H3K27me3, and that in response to serum 
deprivation CXCR4 is upregulated and the H3K27me3 mark is lost. We therefore 
sought to determine whether serum deprivation would convert CXCR4negative cells 
to CXCR4positive cells.  TC32 cells were sorted into CXCR4negative and 
CXCR4positive populations and replated under standard culture conditions 
overnight.  The cells were then exposed to either serum containing or serum 
deprived conditions for 24 hours (Figure 3.6A).  We confirmed our previous 
findings that CXCR4 expression correlated directly with H3K4me3 and inversely 
	   87	  
with H3K27me3 marks in the serum containing culture conditions even 48 hours 
post sort (data not shown).  We found that CXCR4 expression was upregulated 
in response to serum deprived conditions in both the CXCR4negative and 
CXCR4positive populations, though the CXCR4negative population upregulated 
CXCR4 more robustly (Figure 3.6B).  Despite the upregulation of CXCR4 in both 
the CXCR4negative and CXCR4positive populations, the enrichment of H3K27me3 
was decreased only in the CXCR4negative population in response to serum 
deprivation (Figure 3.6C).  As expected, the H3K4me3 mark was unaffected in 
either population (CXCR4negative or CXCR4positive) in response to serum deprived 
conditions (Figure 3.6D).  These data suggest that the majority of the 
CXCR4negative cells reside in a bivalent state which allows them to be more 
responsive to microenvironmental cues than the CXCR4positive population.  The 
observation that the CXCR4positive population upregulated CXCR4 suggests that 
there might be other factors, epigenetic or otherwise contributing to CXCR4 
regulation. 
 
Figure 3.6. CXCR4 sorted cells upregulate CXCR4 in response to serum deprivation.  TC32 
cells were sorted into CXCR4negative and CXCR4positive populations (A).  The two sorted cell 
populations were then maintained under standard culture conditions for 24 hours post sort and 
were then placed into serum replete or serum deprived conditions for 24 hours (A).  In response 
to serum deprived conditions both the CXCR4negative and CXCR4positive populations upregulated 
CXCR4 (B). In response to upregulation of CXCR4, only the CXCR4negative population lost the 
repressive, H3K27me3, mark at the CXCR4 promoter (C).  There was no change in H3K27me3 
enrichment in the CXCR4positive population (C).  Additionally, there was no change in H3K4me3 
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enrichment in response to serum deprivation in either the CXCR4negative or CXCR4positive 
populations (D).  Results shown as mean ± SEM (n=3 for CXCR4 expression, n=2 for ChIP 
experiments). 
 
An upstream enhancer contributes to CXCR4 regulation 
In addition to promoter regulation of gene expression, enhancers have 
been shown to regulate transcription independently of promoter regions.  We 
therefore hypothesized that alterations at an enhancer region may also contribute 
to CXCR4 regulation in response to stress.  In HeLa cells there is a presumed 
enhancer upstream of CXCR4 as characterized by the presence of H3K4me1 
and H3K27ac histone marks (Figure 3.7A) (20-22). To determine if an enhancer 
exists upstream of CXCR4 in Ewing sarcoma cells, four sets of primers were 
designed for this region (Figure 3.7A).  In a panel of five Ewing sarcoma cell lines 
as well as HeLa cells, there was enrichment of the enhancer histone marks 
H3K4me1 and H3K27ac suggesting an enhancer element exists upstream of 
CXCR4 and may play a role in CXCR4 regulation (Figure 3.7B). 
To address whether this enhancer is contributing to CXCR4 regulation, we 
took advantage of an enhancer antagonist, JQ1.   JQ1 is a potent and selective 
inhibitor of the BET family of bromodomains functioning to displace 
bromodomains from chromatin by binding competitively to acetyl-lysine 
recognition marks (23).  We treated Ewing sarcoma cells with sub-cytotoxic 
doses of JQ1 (1 µM) for 24 hours and examined CXCR4 expression.  JQ1 
treatment resulted in down-regulation of CXCR4 expression in HeLa, A673, 
CHLA-25, and TC32 cells but had no effect on CXCR4 expression in TC71 cells 
(Figure 3.7C).  We also demonstrated that JQ1 blocks the CXCR4- toCXCR4+ 
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cell state transitions in response to hypoxic stress (Figure 3.7D) and serum 
deprivation (Figure 3.7E).  Furthermore, exposure of the CHLA-25 and TC32 
cells to JQ1 significantly inhibited their chemotactic migration (Figure 3.7F) and 
invasion (Figure 3.7G) to SDF-1.  Collectively these data suggest that an 
enhancer also contributes to CXCR4 regulation.  Furthermore, enhancer 
dependent regulation of CXCR4 transcription opens the door to the potential of 
epigenetic modifiers as novel therapeutics that could be used to antagonize 
metastasis-promoting cell state transitions. 
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Figure 3.7. An enhancer exists upstream of CXCR4 and contributes to CXCR4 regulation.  
An enhancer element exists upstream of the CXCR4 gene in HeLa cells (encode database) as 
characterized by the presence of the H3K4me1 and H3K27ac marks and may be an additional 
site of CXCR4 regulation (A). Primers were designed for the presumed CXCR4 enhancer region 
(A). Chromatin immunoprecipitation (ChIP) followed by quantitative PCR (qPCR) was used to 
assess the absence or presence of the H3K4me1 and H3K27ac marks at the presumed enhancer 
element in Ewing sarcoma cells and in HeLa cells (B).  The enrichment of H3K4me1 and 
H3K27ac at this locus confirmed the presence of an enhancer element (B).  In support of 
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enhancer function, exposure of Ewing sarcoma cells to the bromodomain inhibitor JQ1, which 
antagonizes enhancer activity, inhibited CXCR4 transcription (C). Treatment of Ewing sarcoma 
cells with JQ1 prevented the upregulation of CXCR4 in response to stress; hypoxia (D) and 
serum deprivation (E).  Additionally, JQ1 inhibited in vitro chemotactic migration (F) and invasion 
(G) of CHLA-25 and TC32 cells to SDF-1α. Results shown as mean ± SEM (n=3).  
 
DISCUSSION 
In this chapter, we have demonstrated that stress-dependent induction of 
CXCR4 in Ewing sarcoma is, in part, epigenetically regulated. In particular, the 
CXCR4 promoter in at least some CXCR4negative Ewing sarcoma cells resides in a 
bivalent state, which permits rapid and reversible transitions between CXCR4- 
and CXCR4+ cell states. Specifically, exposure of Ewing sarcoma cells to serum 
deprivation or hypoxia resulted in loss of bivalency in both bulk populations as 
well as FACS-sorted CXCR4- cells, as evidenced by loss of H3K27me3 with 
retention of H3K4me3 modifications. Loss of bivalency was accompanied by 
upregulation of CXCR4. In addition, we noted that an active enhancer exists 
upstream of the CXCR4 locus and demonstrated that this enhancer also 
contributes to the epigenetic regulation of CXCR4 in Ewing sarcoma. In support 
of this, JQ1 treatment of Ewing sarcoma cells resulted in marked down-regulation 
of CXCR4 expression in ambient conditions. In addition, JQ1 treatment blocked 
up-regulation of CXCR4 in response to both serum deprivation and hypoxia.  Our 
findings lead us to propose a new model of Ewing sarcoma cell heterogeneity in 
which microenvironmental cues lead to CXCR4- to CXCR4+ cell state transitions, 
transitions which are, in part, epigenetically regulated at the CXCR4 locus 
(promoter and enhancer) (Figure 3.8).   
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Figure 3.8.  Model of CXCR4 regulation at the promoter and enhancer.  Under standard 
culture conditions Ewing sarcoma cells maintain the CXCR4 promoter in a bivalent state with the 
simultaneous presence of both the H3K27me3 and H3K4me3 histone modifications. Additionally, 
there is an enhancer upstream of CXCR4 that is characterized by the enrichment of the 
H3K4me1 and H3K27ac histone modifications.  Under conditions of stress such as, serum 
deprivation and hypoxia, CXCR4 is converted from a poised, inactive state to a univalent, active 
state through the loss of the repressive, H3K27me3, mark.  The loss of this mark results in the 
upregulation of CXCR4 expression.  The upregulation of CXCR4 creates a subpopulation of cells 
with increased metastatic potential.  Additionally, the enhancer contributes to the regulation of 
CXCR4, though the precise mechanisms of this upregulation remain to be elucidated. 
 
Thus far, studies of cancer biology and clinical trial development have 
failed to address the inherent heterogeneity and phenotypic plasticity of tumor 
cells (24). This is, in part, due to that fact that the underlying mechanisms 
mediating tumor heterogeneity and plasticity remain largely unknown (25).  
However, recent published findings, in addition to our current data, demonstrate 
that cancer cell plasticity is mediated epigenetically through the resolution of 
bivalent domains. In particular, Chaffer and colleagues identified that non-CSCs 
are plastic populations with the ability to convert to CSCs (26).  They 
demonstrated that this plasticity was dependent on a master regulator of the 
epithelial-to-mesenchymal transition, Zeb1 (26).  In basal CD44lo non-CSCs, 
Zeb1 is maintained in an inactive, poised (bivalent) state and in response to the 
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microenvironmental cue, TGFβ, the bivalent Zeb1 promoter resolves into an 
activate chromatin configuration resulting in basal CD44hi CSCs (26).  Of 
importance, luminal CD44lo non-CSCs did not possess the ability to convert to 
CD44hi CSCs due to the findings that the Zeb1 promoter was maintained in a 
repressed, “off” state rather than a bivalent state (26).  Another study recently 
assessed whether or not ovarian cancer cells were responsive to 
microenvironmental cues and if this response was epigenetically mediated (27).  
They demonstrated that culturing ovarian cancer cells in three-dimensional 
culture conditions as compared to two-dimensional culture conditions altered 
histone modifications and affected gene expression (27).  These findings 
demonstrate that epigenetic mechanisms control tumor cell plasticity, whether in 
the context of Zeb1 transitions in breast cancer, multivalent marks in ovarian 
cancer cells, or CXCR4 transitions in Ewing sarcoma.  Given these findings, it 
would be important to consider the use of adjuvant therapies targeted at 
preventing these conversions. 
It has been well documented that in addition to the heterogeneous 
expression of CSC markers, the makeup of CSCs varies from patient to patient 
(28-30).  In the context of Ewing sarcoma we have also demonstrated that 
CXCR4 expression is heterogeneous across cell lines and tumors (1).  
Furthermore, CXCR4 plasticity is not a universal property across Ewing sarcoma 
cell lines.  Notably, our previous work demonstrated that not all Ewing sarcoma 
cells uniformly upregulate CXCR4 in response to serum deprivation (1). Some 
cells are more plastic than others: TC32 and CHLA-25 cells are highly plastic and 
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responsive while TC71 cells are relatively unresponsive.  This was also evident 
in the pattern of histone modifications.  TC32 cells rapidly converted from a 
bivalent inactive state to a univalent active state whereas TC71 cells were “stuck” 
in a repressed, inactive state even after exposure to serum-deprived conditions.  
These findings underscore to the complex nature of tumor heterogeneity as seen 
in the clinic. 
Thus far, our preliminary studies have demonstrated that an enhancer 
exists upstream of CXCR4 and contributes to the regulation of CXCR4.  We have 
specifically demonstrated that the enhancer region upstream of CXCR4 resides 
in an inactive/poised state under basal culture conditions characterized by the 
H3K4me1 and H3K27ac marks. We have some preliminary data to suggest that 
enrichment of activating marks is increased at the enhancer under conditions of 
stress; however, further studies are necessary to confirm these findings. 
Furthermore, to definitively demonstrate that JQ1 is functioning by disrupting the 
BET family of bromodomain containing proteins at the CXCR4 enhancer 
mentioned above, ChIP-PCR experiments are needed to assess the binding of 
BET bromodomains at the CXCR4 enhancer prior to and following JQ1 
treatment.  JQ1 has high specificity for the BET bromodomain family member, 
BRD4, and thus these experiments should be initially conducted to analyze 
BRD4 binding (31).  These studies will help further define the precise contribution 
of the enhancer to CXCR4 regulation.  
The mechanisms underlying gene expression are complex and vast.  It is 
very possible that epigenetic regulation is not the only process mediating CXCR4 
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plasticity, and that the dynamic regulation of CXCR4 is dependent on 
transcription factor binding in addition to changes in the chromatin state.  To 
address this, designing a CXCR4-promoter luciferase reporter would allow us to 
assess the contribution of chromatin-independent transcriptional regulation of 
CXCR4 in the context of stress. Site-directed mutagenesis of the exogenous 
CXCR4 promoter construct would then be performed to systematically determine 
which regions in the promoter, and thereby which transcription factors, are 
responsible for the dynamic regulation of CXCR4.   
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CHAPTER FOUR 
 
DEVELOPING NOVEL MODELS TO STUDY CXCR4 IN EWING SARCOMA 
METASTASIS IN VIVO 
 
 
OBJECTIVE STATEMENT 
In this chapter I describe the development and testing of novel models 
designed to analyze the role of CXCR4 in Ewing sarcoma metastasis. In addition, 
these tools will allow further evaluation of the emergence of CXCR4 
heterogeneity during Ewing sarcoma progression in vivo. 
 
PART ONE 
 
BACKGROUND AND RATIONALE 
 
In Chapter Two, we demonstrated that CXCR4 promotes migration and 
invasion in vitro (1).  While migration and invasion are both integral parts of the 
metastatic cascade, to definitively determine the contribution of CXCR4 to Ewing 
sarcoma metastasis, in vivo models are essential. Human-mouse xenograft 
models are considered the gold standard for studying metastasis.  These models 
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consist of the transplantation of human cell lines or tumors into 
immunocompromised animals (mice or rats).  There are two types of 
experimental approaches to study metastasis using these xenograft models: the 
experimental metastasis model and the spontaneous metastasis model (2). 
The experimental metastasis model is the most widely used model to 
study metastasis and refers to the injection of cells directly into the circulatory 
system (2). These models test the ability of cells to arrest, extravasate and grow 
in various organs.  Unfortunately, these models bypass the first few steps of the 
metastatic cascade as discussed in Chapter One.  The most common 
experimental metastasis model is the tail vein injection model, in which cells are 
injected in the lateral tail vein of mice or rats. Other common injection sites 
include intrasplenic injections, portal vein injections, and intracardiac injections 
(3-5).  In these models, tumor cell colonization is often limited to the lungs as it is 
the first capillary bed the tumor cells reach following injection.  Thus far, the 
majority of Ewing sarcoma metastasis studies have used the tail vein injection 
model (6, 7). 
The spontaneous metastasis model allows cells to disseminate from a 
local, primary tumor to a distant, secondary site.  Traditionally, these models 
have consisted of tumor cell injections or tumor implantations into a 
subcutaneous (flank) site. These injection or implantation sites have been 
favored because it provides an environment for rapid primary tumor growth.   
These subcutaneous tumor implantations are often used for screening potential 
anti-neoplastic agents (8).  While this model is good for studying primary tumor 
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growth, spontaneous metastases to distant sites are very rare (2), limiting its use 
as a model of metastasis. The preferred spontaneous metastasis model is the 
orthotopic spontaneous model, in which cancer cells are injected into an 
anatomical location that mimics the clinical presentation of a particular cancer. 
For example, the mammary fat pad is an orthotopic site for breast cancer and the 
adrenal gland is an orthotopic site for neuroblastoma (9, 10). These orthotopic 
models readily recapitulate human disease as demonstrated through histology, 
growth characteristics, angiogenesis, and metastatic behavior (2).  While these 
orthotopic spontaneous models are the best at recapitulating the characteristics 
of clinical disease, they are technically challenging, time consuming, and can be 
costly to perform.  To understand the contribution of CXCR4 to Ewing sarcoma 
metastasis, it is essential to use the appropriate model.  This is critical as 
studying Ewing sarcoma metastasis has proven to be challenging due to the lack 
of a genetically engineered mouse model. 
In Ewing sarcoma literature, all of the aforementioned models have been 
used to study different aspects of Ewing sarcoma biology as well as others.  
Recently, Mendoza-Naranjo et al. described the use of renal subcapsular 
implantation model to study Ewing sarcoma metastasis (11).  They argued that 
the tissue underlying the renal capsule is highly vascularized, allowing for the 
rapid formation of macroscopic metastases as compared to subcutaneous or 
other orthotopic models.  In their model, Ewing sarcoma cells were implanted into 
the exteriorized kidneys of anaesthetized live mice.  While this model was 
effective for their study, it was an extremely invasive procedure.  We were 
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fortunate to have the opportunity to collaborate with Dr. Erika Newman who has 
optimized an innovative and minimally invasive orthotopic xenograft model which 
utilizes ultrasound guidance to implant cells into the subrenal capsule.   This 
model has been previously described wherein neuroblastoma cells are 
orthotopically injected using ultrasound guidance into the adrenal or para-adrenal 
space (12).  We decided to modify the previously described model in order to be 
able to inject Ewing sarcoma cells into the subrenal capsule.  Successful 
development of this model in our laboratory would allow us to efficiently study 
Ewing sarcoma metastasis.  As this model was first reported using 
neuroblastoma cells, our initial optimization and protocol development was 
conducted using neuroblastoma cells. 
 
MODEL DEVELOPMENT 
 
The experimental procedures for the subrenal capsule injection model are 
detailed as follows: 1.0x106 GFP/Luciferase (LUC) tagged human tumor cells 
(neuroblastoma/Ewing sarcoma) were resuspended in PBS and Matrigel™ (1:1) 
(BD Worldwide, 354234) at a concentration of 2.0x104 cells per microliter and 
placed on ice.  Nine week-old NOD SCID mice (Charles River Breeding Labs, 
394) were anesthetized in an induction chamber using 2% isoflurane in O2 
delivered at 2 liters/minute.  Once anesthetized, the dorsal hair of the mouse was 
removed with the commercial depiliating agent, Nair.  The animal was then 
transferred to the imaging table ventral side down, where isoflurane was 
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delivered via a nose cone for inhalation at 1.5% in O2 delivered at 2 liters/minute. 
The mouse was restrained and taped to insure taut skin and optical ointment was 
placed in the animal’s eyes to prevent them from drying out.  A chilled 22-gauge 
catheter (BD Worldwide, 381423) was gently inserted through the skin and back 
muscle into the subrenal capsule to provide a channel for the needle injection. 
After removal of the hub, a chilled Hamilton syringe fitted with a 27 gauge bore 
needle (BD Worldwide, 60476-220) loaded with 10µl of the cell suspension (2.0 x 
105 total cells) was guided steretoactically through the catheter and positioned 
into the subrenal capsule visualized using ultrasound (Figure 4.1A).  The cells 
were injected into the subcapsular space and the needle was left in for one 
minute allowing the Matrigel™ to set.  The needle was slowly removed, followed 
by removal of the catheter. All ultrasound procedures were performed using the 
Vevo 2100 High-Resolution In Vivo Imaging System with the MS 550D 
transduced with a center frequency of 40 MHz and a bandwidth of 22-55 MHz 
(Cardiovascular Center Research Core Lab, University of Michigan).  
Bioluminescent imaging was performed on the Perkin Elmer In Vivo IVIS 
Spectrum Optical Imaging System (Center for Molecular Imaging Core, 
University of Michigan). 
We confirmed that these injections could be successfully completed in our 
laboratory.  Our initial studies were conducted using neuroblastoma cells, which 
were injected into the peri-adrenal space (Figure 4.1A).  We also confirmed that 
we could successfully inject methlyene blue/Matrigel™ in the subrenal capsule, 
which allowed us to proceed with experimental studies  (Figure 4.1B and C).   
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Figure 4.1. Subrenal capsule model of tumor progression in vivo.  A. Guided by ultrasound, 
neuroblastoma cells were injected into the peri-adrenal space. A large peri-renal tumor is 
detected at necropsy and a metastatic lesion is detected by bioluminescent imaging. The 
subrenal capsule approach will be used for ES studies. B. Ultrasound image of percutaneous 
injection of the subrenal capsule. C. Image of excised kidney following injection of methylene 
blue/Matrigel™ into the subrenal capsule.  
 
RESULTS 
 
Ewing sarcoma in vivo metastasis models 
Upon demonstrating that our laboratory can successfully inject “tumor 
cells” into the subrenal capsule, we wanted to determine if this innovative 
technique would provide a model to study Ewing sarcoma metastasis.  Despite 
the aforementioned disadvantages of other xenograft models, we felt that it was 
necessary to compare the subrenal capsule model to other established Ewing 
sarcoma xenograft models. We decided to compare the following models: the 
subcutaneous injection model, the tail vein injection model, and the subrenal 
capsule injection model. 
We tested a panel of Ewing sarcoma cell lines and compared their ability 
to metastasize in each of the models (detailed experimental procedures are 
outlined in the legend of Table 4.1).  As expected with the subcutaneous 
injections, none of the cell lines metastasized  (Table 4.1A).  Interestingly, not all 
B C A 
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of the cell lines developed tumors at the site of injection; CHLA-25 cells did not 
form any primary tumors (Table 4.1A). These findings suggest that tumorigenic 
heterogeneity exists across Ewing sarcoma cell lines.  For the tail vein injection 
model, A673 and TC32 cells readily formed tumors while TC71 and CHLA-25 
cells did not (Table 4.1B).  This again highlights tumorigenic heterogeneity. For 
the subrenal capsule model, all of the cell lines we tested (A4573, A673, CHLA-
25, and TC32) readily formed tumors at the site of injection (A4573 had two 
misinjections) (Table 4.1C).  A4573 and TC32 were the only two cell lines to 
develop metastases.  Metastases were evident in the lung with frequencies of 
40% for TC32 cells and 33% for A4573 cells (Table 4.1). 
 
Table 4.1. Summary of in vivo metastasis model pilot study. A. CHLA-9, A673 and TC32 
cells readily formed tumors at the site of injection in the subcutaneous model.  CHLA-25 cells did 
not form tumors.  None of the cell lines exhibited metastases. B.  A673 and TC32 formed tumors 
in the tail vein injection model whereas TC71 and CHLA-25 cells did not.  C. A4573, A673, CHLA-
25, and TC32 cells all formed primary tumors and only A4573 and TC32 cells metastasized from 
the subrenal capsule.  The subcutaneous and tail vein injections were performed as previously 
described (13).  In brief, for the subcutaneous model 1.0x106 A673, CHLA-9, CHLA-25 or TC32 
cells with injected with Matrigel™ (1:1 ratio) into the flank of 8 week-old NOD-SCID mice (10 mice 
per cell line).  For the tail vein model, 1.0x106 A673, CHLA-9, CHLA-25 or TC32 cells with 
injected into the lateral tail vein of 8 week-old NOD-SCID mice (3 mice per group). 
 
From this pilot study, we have determined that the subrenal capsule model 
is the preferred model to study the contribution of CXCR4 to Ewing sarcoma 
Subcutaneous Injections  Tail Vein Injections  Subrenal Capsule Injections 
 Primary Tumor Metastases  Tumor Presence  Primary Tumor 
Lung 
Metastases 
Cell Line Number of mice/Total mice (%) Cell Line 
Number of mice/Total 
mice (%) Cell Line 
Number of mice/Total mice 
(%) 
CHLA-9 10/10 (100%) 0/10 (0%) TC71 0/3 (0%) A4573 3/5 (60%) 1/3 (33%) 
A673 10/10 (100%) 0/10 (0%) A673 3/3 (100%) A673 4/5 (80%) 0/5 (0%) 
CHLA-25 0/10 (0%) 0/10 (0%) CHLA-25 0/3 (0%) CHLA-25 5/5 (100%) 0/5 (0%) 
TC32 10/10 (100%) 0/10 (0%)  TC32 3/3 (100%)  TC32 5/5 (100%) 2/5 (40%) 
A B C 
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spontaneous metastasis. Furthermore, given that TC32 cells readily metastasize 
(40%) and have high expression levels of CXCR4, this cell line was chosen to 
study the contribution of CXCR4 to Ewing sarcoma metastasis. 
 
The innovative subrenal capsule model was used to determine the 
contribution of CXCR4 to Ewing sarcoma metastasis 
To test the contribution of CXCR4 to the metastatic cascade in vivo, we 
used the aforementioned subrenal capsule xenograft model.  We hypothesized 
that knockdown of CXCR4 in Ewing sarcoma cells would reduce the 
development of metastases.  We used TC32 cells with stable knockdown of 
CXCR4 (shCXCR4) and TC32 cells with an inert non-silencing sequence (shNS) 
for the in vivo studies (both generated using previously described short hairpin 
RNA constructs) (1, 14).  CXCR4 knockdown was confirmed in the cells prior to 
injection (Figure 4.2A).  Ten mice were injected with 2.0x105 GFP/luciferase 
(LUC) labeled TC32 shNS or TC32 shCXCR4 cells into the subrenal capsule of 8 
week-old NOD-SCID mice. The TC32 shNS and TC32 shCXCR4 groups were 
compared with respect to time to engraftment, tumor size, and evidence of 
metastatic disease. 
Weekly bioluminescence imaging demonstrated that both control and 
CXCR4 knockdown cells formed tumors with an 80% success rate (8 out of 10 
mice per group developed tumors) (Figure 4.2B).  Interestingly, there was little 
difference in total body bioluminescence signaling (p/sec/cm2/sr) between the 
shNS and shCXCR4 tumors between weeks 1 and 4, post injection (Figure 
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4.2C).  However, at 5 weeks post injection there appeared to be a trend towards 
the CXCR4 knockdown tumors decreasing size as determined by radiance 
(Figure 4.2C).  These data suggest that CXCR4 may play a role in promoting 
Ewing sarcoma tumor growth at local sites. 
At 6 weeks post injection, the primary tumors were excised, measured and 
ex vivo imaging was performed to determine the presence of any metastases.  
Upon mouse necropsy, it was confirmed that 2 mice per group had no evidence 
of primary tumor formation, which corroborated the bioluminescent findings 
(Figure 4.2B).  Primary tumor volume (mm3) was calculated using the formulation 
V = L x W x D where L is length, W is width and D is depth. There was marked 
variability in tumor volume in both groups (Figure 4.2D).  Though not statistically 
significant (p = 0.19), there was a definite trend toward CXCR4 promoting tumor 
growth based on tumor volume (Figure 4.2D). 
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Figure 4.2. CXCR4 may contribute to primary tumor growth.  A. CXCR4 knockdown was 
confirmed in GFP/LUC TC32 shCXCR4 cells as compared to the GFP/LUC TC32 shNS. B. An 
80% injection success rate as observed in both shNS and shCXCR4 groups defined as >106 
p/sec/cm2/sr.  C. Bioluminescent imaging (radiance) showed a trend towards CXCR4 knockdown 
inhibiting tumor growth.  D. Tumor volume supports bioluminescent findings with tumor volumes 
trending towards smaller in the CXCR4 knockdown group. 
 
For the ex vivo imaging, each mouse was injected with luciferin, and 
subsequently euthanized five minutes post injection.  The primary tumor was 
then removed and the mouse carcass was imaged to determine if metastases 
were present.  A single bioluminescent image was captured and whole body 
ROIs (region of interest) were determined based on the single capture per 
mouse.  There was no difference in total body radiance between the shNS and 
shCXCR4 groups (Figure 4.3A).  These findings were inconclusive due to the 
Weeks Post 
Injection shNS shCXCR4 
Week 1  6/10  6/10 
Week 2  6/10  6/10 
Week 3  7/10  6/10 
Week 4  7/10  7/10 
Week 5  8/10  8/10 
A B 
C D 
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residual blood that remained and generated a signal in the mouse cavity after 
primary tumor resection (Figure 4.3B). 
 
Figure 4.3. Ex vivo imaging demonstrated no difference in metastatic formation.  A. There 
was no difference in ex vivo radiance after primary tumor resection. B. Residual blood spillage 
into the mouse cavity was evident on bioluminescent imaging following primary tumor resection. 
 
qRT-PCR was performed to confirm that the tumors maintained CXCR4 
knockdown in the TC32 shCXCR4 group.  Surprisingly, there was no statistical 
difference (p=0.39) in CXCR4 expression in the non-silencing tumors and the 
CXCR4 knockdown tumors. (Figure 4.4A).  These findings suggest that there 
was a selective advantage in vivo in favor of CXCR4 expressing cells.  Despite 
the outgrowth of CXCR4+ cells, the two largest tumors had the highest CXCR4 
expression (yellow), and the five smallest tumors had the lowest CXCR4 
expression (red) (Figure 4.4B).  When plotting CXCR4 expression against tumor 
volume (15 tumors; 8 shNS and 7 shCXCR4), there is a moderate correlation (r = 
0.53) between tumor volume and CXCR4 expression with the largest tumors 
having the highest CXCR4 expression and the smallest tumors having the lowest 
A B 
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CXCR4 expression (Figure 4.4C-D).  These data further support our radiance 
and volume findings that CXCR4 may be contributing to tumor growth in vivo. 
 
Figure 4.4. Tumor volume correlates with CXCR4 expression.  A. There was no difference in 
CXCR4 expression between the shNS and shCXCR4 tumor groups. B. The tumors with the 
largest volume expressed high levels of CXCR4 (yellow) and the tumors with the lowest volume 
expressed the lowest levels of CXCR4 (red). C. A moderate positive correlation exists between 
tumor volume and CXCR4 expression. D. The correlation coefficient values from 4.4C plot are 
reported. 
 
DISCUSSION 
 
Out of the three models tested, we determined that the subrenal capsule 
mouse xenograft model was the best in vivo platform to study metastasis. This 
Tumor Volume vs. CXCR4 Expression 
Pearson r  
r 0.5313 
95% confidence interval 0.02612 to 0.8203 
R squared 0.2823 
  
P value  
P (two-tailed) 0.0416 
P value summary * 
Significant? (alpha = 0.05) Yes 
  
Number of XY Pairs 15 
A B 
C D 
TC32 shNS  TC32 shCXCR4 
Tumor 
Volume 
(mm3) 
CXCR4 
Expression 
(2-!ct) 
Tumor 
Volume 
(mm3) 
CXCR4 
Expression 
(2-!ct) 
827 1.64 7433 4.19 
1251 1.24 3263 0.54 
5577 2.81 68 0.87 
8935 4.21 3205 1.61 
6000 1.94 975 0.58 
5625 2.36 1800 4.30 
4500 4.46 1500 N/A 
675 1.49  488 0.93 
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model allows us to study the metastatic cascade in its entirety.  However, the 
kidney is not a usual site for Ewing sarcoma development.  The most common 
primary sites for Ewing sarcoma are the long bones including the femur (20%), 
the humerus (6.0%) the tibia (10%) and the fibula (8.0%) (15). While there have 
been documented cases of Ewing sarcoma cases in the kidney, they are very 
rare (16).   To further facilitate a clinically relevant site, intra-femoral or intra-tibial 
metastasis models have been widely used as the bone microenvironment plays a 
key in the Ewing sarcoma pathogenesis (17).  While we believe that the subrenal 
capsule model is an appropriate model to study Ewing sarcoma metastasis, 
current studies are being implemented in the laboratory to optimize the intra-tibial 
model. 
Using the subrenal capsule model to test the contribution of CXCR4 to 
Ewing sarcoma metastasis, our preliminary studies suggest that CXCR4 may 
contribute to Ewing sarcoma primary tumor growth in vivo.  Our data is further 
supported by findings from D Berghuis, et al., which demonstrated that CXCL12 
stimulation of CXCR4hi Ewing sarcoma cells promotes proliferation in vitro (18). 
Furthermore, they argued that CXCR4 does not promote metastasis in Ewing 
sarcoma. While not conclusive, due to blood spillage into the mouse cavity, we 
saw no difference in metastatic formation between shNS and shCXCR4 in our 
studies.  However, our findings were complicated by the fact that there was a 
selective pressure against CXCR4lo cells in vivo.  We demonstrated that the 
tumors lost CXCR4 knockdown as the shCXCR4 tumors had comparable 
CXCR4 expression levels to the shNS tumors.  To definitively determine the role 
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of CXCR4 in Ewing sarcoma tumorigenesis further studies are necessary to 
eliminate the outgrowth of CXCR4 expressing cells in the knockdown population.   
 
PART TWO 
 
BACKGROUND AND RATIONALE 
 
Stable RNA interference (RNAi) is a powerful scientific tool to evaluate 
protein function. However, as demonstrated above, it is limited by incomplete 
loss-of-function of the targeted gene as well as off-target effects that can result 
from random integration of the shRNA sequence into the genome.  Recently, 
new genome-editing technologies, including TALENS and CRISPR/Cas9 have 
been developed that allow for direct-targeted disruption and modification of 
endogenous genes. The primary advantages of using the CRISPR/Cas9 gene 
targeting approach as are as follows: (a) simple and cost-effective means to 
generate cell lines in comparison to conventional knockout approaches; (b) 
specifically targeted small mutations can be introduced; (c) no integration of 
vector DNA occurs; and (d) no selection is needed (19).  We sought to generate 
a CXCR4 knockout cell line using the CRISPR/Cas9 system.  These cell lines will 
be essential tools that can be used in future in vivo studies to eliminate the 
outgrowth of CXCR4high cells as demonstrated above.  This will allow us to truly 
define the contribution of CXCR4 to Ewing sarcoma pathogenesis. 
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We have recently shown that expression of CXCR4 is dynamic and that 
Ewing sarcoma cells transition between a relatively non-motile CXCR4- state to a 
more migratory CXCR4+ state in response to microenvironmental cues, including 
hypoxia, growth factor deprivation, and growth constraints (1).  These cell state 
transitions have been demonstrated in vitro in a pooled population of cells but 
have yet to be characterized in vivo and on a single cell level.  To monitor these 
transitions on a single cell level we sought to generate a CXCR4-GFP knock-in 
reporter cell line (experimental details outlined below).  
 
RESULTS 
 
Generating CXCR4 knockout cells 
In collaboration with Clontech, four different sgRNAS were developed to 
target CXCR4 (Table 4.2).	  The sgRNAs were designed to target both isoforms of 
CXCR4 using http://crispr.mit.edu/ and http://chopchop.rc.fas.harvard.edu/. 
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Table 4.2. CXCR4 targeting sgRNA sequences. Table of oligo sequences designed to target 
CXCR4 for knockout studies. Red letters for each oligo are the overhang sequence.  The 
antisense oligo is complementary to the sense oligo. 
 
The sgRNA cleavage efficiency was tested using the Guide-it Mutation 
Detection Kit and determined that sgRNAs #1, #2, and #4 were effective in the 
cleavage of the target sequence where sgRNA #3 demonstrated ineffective 
cleavage (Clontech, 631438) (Figure 4.5A).  The sgRNAs were then successfully 
cloned into the all in one Guide-it™ CRISPR/Cas9 System (Red) per the 
manufacturer’s instructions (Clontech, 632602). Confirmation of cleavage was 
determined by using the Guide-it sgRNA In Vitro Transcription Kit. Plasmids were 
transfected using the Xfect™ Transfection Reagent (Clontech, 631318).  Cells 
were then sorted on the basis of tdTomato as previously described (1). 
To test the constructs, HeLa cells were used as a sample cell line due to 
the high expression of CXCR4 with nearly 100% of the cells expressing CXCR4 
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on their cell surface (20).  We have successfully generated CXCR4 knockout 
HeLa cells (Figure 4.5B).  Generation of CXCR4 knockout clones will be 
continued in two Ewing sarcoma cell lines, CHLA-25 and TC32.  We chose these 
cell lines as they express high levels of CXCR4 at baseline.  Upon successful 
generation of the knockout cell lines, functional studies will be used to assess for 
an inhibition of CXCR4-mediated in vitro migration and invasion.  These cells will 
be used in in vivo future metastasis studies (See subrenal capsule injection 
model) to determine the contribution of CXCR4 to Ewing sarcoma metastasis by 
eliminating the potential of CXCR4high cell outgrowth.   
 
Figure 4.5. CXCR4 knockout cells.  A. The cleavage efficiency of 4 sgRNAs was determined.  
Oligo #3 is the least effective at cleavage of the target sequence.  B. HeLa knockout CXCR4 cells 
were successfully generated using oligos #2. 
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In collaboration with Sigma, we are generating a CXCR4 knock-in cell line 
in which GFP is fused in-frame with CXCR4.  Two sgRNAs were designed to 
target the CXCR4 stop codon (Figure 4.6A).  Ongoing studies are being 
conducted to validate if the CRISPRs are cleaving at the appropriate site and 
how efficient they are at cutting using the Guide-it™ Mutation Detection Kit 
(Figure 4.6B).  Upon validation of the sgRNAs, a donor plasmid with homologous 
arms will be designed to carry in GFP into the cut site (Figure 4.6C). Clones will 
be screened for GFP expression and then sequence validated (Figure 4.6D).  
These cells will be used for future in vitro and in vivo studies to visualize changes 
in CXCR4 expression on a single cell basis. 
 
Figure 4.6. Schematic of CXCR4-GFP knock-in reporter cell line work flow.  A. sgRNAs are 
designed to cut within 300 bp of the CXCR4 stop codon. B. The activity of the sgRNAs is 
validated using the Guide-it™ Mutation Detection Kit.  C. Upon validation that the sgRNAs cut 
effectively, homology arms are designed that will carry in the GFP to the cut site. D. Clones will 
be screened for GFP expression and validated by sequencing to generate CXCR4-GFP knock-in 
Ewing sarcoma cell lines. 
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To overcome the challenges uncovered in the in vivo metastatic Ewing 
sarcoma study, we sought to generate CXCR4 knockout cells.  These cells will 
allow us to establish the contribution of CXCR4 to the metastatic cascade in a 
more precise manner.  In Chapters Two and Three, we demonstrated that Ewing 
sarcoma cells upregulated CXCR4 in response to stress.  However, this 
upregulation of CXCR4 was not uniform across all Ewing sarcoma cell 
lines.  Some cell lines robustly upregulated CXCR4 when exposed to serum 
deprived conditions, while others did not upregulate CXCR4 at all.  How can we 
determine which cells will respond and which cells will not respond?  We are 
generating a CXCR4-GFP knock-in construct using CRISPR/Cas9 in which GFP 
will be fused in frame to CXCR4. This construct will allow us to use GFP as a 
marker for the changes in CXCR4 expression to monitor the cell state transitions 
that occur with respect to CXCR4 on a single cell level.  The development of 
these novel techniques will allow us to determine if CXCR4+ Ewing sarcoma 
cells are key contributors to Ewing sarcoma metastasis.  We will also be able to 
examine the dynamic nature of CXCR4 regulation and its contribution to tumor 
heterogeneity. 
 
SUMMARY STATEMENT 
 
In summary, this chapter outlined the development and testing of a novel 
in vivo model to assess the contribution of CXCR4 in Ewing sarcoma metastasis. 
Furthermore, we are in the process of developing and implementing tools that will 
	   118	  
allow us to further study CXCR4 heterogeneity during Ewing sarcoma 
progression in vivo. 
	   119	  
REFERENCES 
 
1. Krook MA, et al. (2014) Stress-induced CXCR4 promotes migration and 
invasion of ewing sarcoma. Molecular cancer research : MCR 12(6):953-
964. 
 
2. Khanna C & Hunter K (2005) Modeling metastasis in vivo. Carcinogenesis 
26(3):513-523. 
 
3. Kuruppu D, Christophi C, Bertram JF, & O'Brien PE (1996) 
Characterization of an animal model of hepatic metastasis. Journal of 
gastroenterology and hepatology 11(1):26-32. 
 
4. Thalheimer A, et al. (2009) The intraportal injection model: a practical 
animal model for hepatic metastases and tumor cell dissemination in 
human colon cancer. BMC cancer 9:29. 
 
5. Campbell JP, Merkel AR, Masood-Campbell SK, Elefteriou F, & Sterling 
JA (2012) Models of bone metastasis. Journal of visualized experiments : 
JoVE (67):e4260. 
 
6. Sainz-Jaspeado M, et al. (2010) Caveolin-1 modulates the ability of 
Ewing's sarcoma to metastasize. Molecular cancer research : MCR 
8(11):1489-1500. 
 
7. Landuzzi L, et al. (2000) The metastatic ability of Ewing's sarcoma cells is 
modulated by stem cell factor and by its receptor c-kit. The American 
journal of pathology 157(6):2123-2131. 
 
8. Francia G, Cruz-Munoz W, Man S, Xu P, & Kerbel RS (2011) Mouse 
models of advanced spontaneous metastasis for experimental 
therapeutics. Nature reviews. Cancer 11(2):135-141. 
 
9. Kocaturk B & Versteeg HH (2015) Orthotopic injection of breast cancer 
cells into the mammary fat pad of mice to study tumor growth. Journal of 
visualized experiments : JoVE (96). 
 
10. Khanna C, Jaboin JJ, Drakos E, Tsokos M, & Thiele CJ (2002) Biologically 
relevant orthotopic neuroblastoma xenograft models: primary adrenal 
	   120	  
tumor growth and spontaneous distant metastasis. In vivo (Athens, 
Greece) 16(2):77-85. 
 
11. Mendoza-Naranjo A, et al. (2013) ERBB4 confers metastatic capacity in 
Ewing sarcoma. EMBO molecular medicine 5(7):1019-1034. 
 
12. Teitz T, et al. (2011) Preclinical models for neuroblastoma: establishing a 
baseline for treatment. PloS one 6(4):e19133. 
 
13. Shimizu S (2004) Routes of administration. 
 
14. Orimo A, et al. (2005) Stromal fibroblasts present in invasive human 
breast carcinomas promote tumor growth and angiogenesis through 
elevated SDF-1/CXCL12 secretion. Cell 121(3):335-348. 
 
15. Bernstein M, et al. (2006) Ewing's sarcoma family of tumors: current 
management. The oncologist 11(5):503-519. 
 
16. Almeida MF, Patnana M, Korivi BR, Kalhor N, & Marcal L (2014) Ewing 
sarcoma of the kidney: a rare entity. Case reports in radiology 
2014:283902. 
 
17. Vormoor B, et al. (2014) Development of a Preclinical Orthotopic 
Xenograft Model of Ewing Sarcoma and Other Human Malignant Bone 
Disease Using Advanced In Vivo Imaging. PloS one 9(1):e85128. 
 
18. Berghuis D, et al. (2012) The CXCR4-CXCL12 axis in Ewing sarcoma: 
promotion of tumor growth rather than metastatic disease. Clinical 
sarcoma research 2(1):24. 
 
19. Sander JD & Joung JK (2014) CRISPR-Cas systems for editing, 
regulating and targeting genomes. Nature biotechnology 32(4):347-355. 
 
20. Pelekanos RA, et al. (2014) Intracellular trafficking and endocytosis of 
CXCR4 in fetal mesenchymal stem/stromal cells. BMC Cell Biology 15:15-
15. 
	   121	  
 
CHAPTER FIVE 
 
CONCLUSIONS 
 
INTRODUCTION 
 
Ewing sarcoma is the second most common bone malignancy in children 
and adolescents (1).  Although the overall survival for Ewing sarcoma patients 
has improved over the last several decades, metastasis remains the primary 
cause of death (2). However, as metastasis is a complex, multistep process 
influenced by hundreds of factors, many gaps still exist in understanding the 
molecular mechanisms driving Ewing sarcoma tumor metastasis.  Through the 
work of this thesis, we sought to investigate the role of the CXCR4/CXCL12 
chemokine axis as a mediator of Ewing sarcoma metastasis. 
Specifically, we have discovered that CXCR4 promotes Ewing sarcoma 
migration and invasion in vitro (Chapter Two).  Furthermore, we determined that 
CXCR4 is heterogeneously expressed in Ewing sarcoma cell lines and tumors 
and that its expression is highly dynamic (Chapter Two).  We demonstrated that 
CXCR4 is reversibly induced in response to microenvironmental stresses, such 
as serum deprivation, hypoxia, and space constraints, promoting the dynamic 
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transition of cells between nonmigratory/noninvasive (CXCR4-) and 
migratory/invasive states (CXCR4+) (Chapter Two). We next sought to determine 
the precise molecular mechanisms underlying the observed dynamic regulation 
of CXCR4 expression. 
We focused our efforts on defining the epigenetic contribution to CXCR4 
plasticity.  We identified that the CXCR4 promoter exists in a bivalent state, 
which permits rapid and reversible transitions between CXCR4- and CXCR4+ 
cell states in response to microenvironmental cues (Chapter Three). 
Furthermore, we discovered that an enhancer also contributes to CXCR4 
regulation (Chapter Three).  In support of this, the enhancer antagonist, JQ1, 
down-regulated CXCR4 expression in ambient condition as well as blocked up-
regulation of CXCR4 in response to both serum-deprivation and hypoxia 
(Chapter Three). Additionally, JQ1 blocked CXCR4-mediated Ewing sarcoma 
migration and invasion (Chapter Three).  In conclusion, we demonstrate an 
epigenetic mechanism for the regulation of CXCR4 plasticity.  Taken together, 
these findings suggest a potential avenue for the development of new therapeutic 
strategies to block CXCR4 signaling in Ewing sarcoma. 
Additionally, we have tested and developed in vivo models to study Ewing 
sarcoma metastasis.  We used an innovative orthotopic xenograft model to test 
the contribution of CXCR4 to Ewing sarcoma metastasis.  Furthermore, we are 
also in the process of developing new genetic tools and reporters that will be 
used for future experiments to further define the contribution of CXCR4 to Ewing 
sarcoma metastasis. 
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To our knowledge, this work is the first to provide evidence that CXCR4 
contributes to Ewing sarcoma in vitro migration and invasion as well as 
preliminary evidence that CXCR4 contributes to Ewing sarcoma tumor growth in 
vivo.  Additionally, we provide an epigenetic mechanism responsible for 
regulating the dynamic expression of the chemokine receptor, CXCR4 in Ewing 
sarcoma.  Overall, this thesis is significant because it provides evidence that the 
CXCR4/CXCL12 signaling is important in Ewing sarcoma pathogenesis. 
Additionally, this thesis provides an epigenetic mechanism that can be 
therapeutically exploited to eliminate CXCR4- to CXCR4+ cell state transitions. 
 
FUTURE DIRECTIONS 
 
Is CXCR4 plasticity a characteristic of cancer stem cells (CSCs)? 
Tumor heterogeneity remains a major therapeutic challenge, however, the 
mechanisms underlying how tumor heterogeneity arises are poorly understood 
(3). Cancer stem cells (CSCs) have been implicated as key contributors to tumor 
heterogeneity (4).  Within a tumor, CSCs are a rare subpopulation of cells that 
are pluripotent, have the ability to self-renew, and possess tumor-initiating 
capabilities; thus generating heterogeneous tumors that consist of both CSCs 
and non-CSCs (cancer stem cell hypothesis) (5). Additionally, there are 
phenotypic differences between CSCs and non-CSCs including varied rates of 
proliferation, differential migratory and invasive behavior, and altered metastatic 
potential (4).  Unsurprisingly, the percentage of CSCs within any given tumor can 
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drastically vary. CSCs have been identified in many tumor types including 
leukemia, breast, brain, liver, pancreatic, and colon cancer (6-10). Epigenetic 
plasticity is a hallmark of stem cells mediated through a specific epigenetic 
feature—a bivalent chromatin state (11).  As mentioned in Chapter One, bivalent 
chromatin is defined as the simultaneous presence of the active, H3K4me3, and 
repressive, H3K27me3, histone modifications at gene promoters (12, 13).  
Bivalent domains generally silence genes while keeping them poised and ready 
for activation. In response to developmental or microenvironmental cues, these 
domains can then resolve into active states with a predominant H3K4me3 mark, 
or resolve into a repressed states with a predominant H3K27me3 mark (13). 
 In Chapter Three, we demonstrated that a bivalent CXCR4 promoter 
promotes transitions between CXCR4- and CXCR4+ cell states.  These studies 
were conducted in Ewing sarcoma cells lines, which are thought to innately 
behave like stem cells.  In addition to the involvement of the CXCR4/CXCL12 
signaling axis in normal stem cell homing, there is evidence in the literature to 
suggest that CXCR4 may be associated with cancer stem cells (14).  For 
example, CXCR4 surface protein levels have been shown to increase in CD133+ 
human glial-derived CSCs that have been exposed to hypoxic stress (15). In 
pancreatic cancer, populations of CD133+/CXCR4+ CSCs are found on the 
invasive edge of a tumor, which in turn promotes migration (15, 16).  Additionally, 
a study conducted in our laboratory by Dr. Chris Scannell, demonstrated that 
CXCR4 transcript was enriched in slowly proliferating (PKH-dye-retaining) Ewing 
sarcoma cells compared to more rapidly dividing counterparts.  These findings 
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highlight the fact that CXCR4 may be enriched in a subpopulation of CSCs that 
possess increased metastatic potential.  Therefore we hypothesize the 
epigenetic plasticity of CXCR4 is a characteristic of cancer stem cells.  To 
address this hypothesis future studies could be done using breast cancer cell 
lines (e.g. MCF-7 and MDA-MB-231) and glioblastoma cell lines (e.g. U138MG) 
(17-19).  These cell lines were chosen because CSCs have been identified in 
both breast cancer and glioblastoma (20, 21).  Additionally, there are well-
established protocols for the identification and viable isolation of the CSC 
population from these tumor types (22). 
To test our hypothesis, we would initially subject these cell lines (bulk 
populations) to serum deprived and hypoxic conditions and assess any changes 
in CXCR4 expression by qRT-PCR. Preliminary studies have demonstrated that 
some breast cancer cells upregulate CXCR4 expression after serum deprivation 
for 24 hours (SUM159 and MCF7, data not shown).  Based on our findings from 
Chapter Three, we hypothesize that the upregulation of CXCR4 seen in breast 
cancer cells is epigenetically mediated by the loss of the H3K27me3 mark at the 
CXCR4 promoter. To test this hypothesis, Chromatin immunoprecipitation (ChIP) 
experiments would be used to examine changes in the enrichment of the 
H3K4me3 and H3K27me3 histone modifications at the CXCR4 promoter prior to 
and after exposure to serum deprived culture conditions.  These experiments 
could be repeated in glioblastoma cells as well as extended to conditions of 
hypoxic stress.  As we demonstrated in Chapter One and Chapter, not all cells 
within the population upregulate CXCR4.  In order to determine if the CSCs are 
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the cells within a population that are plastic and responsive to stress, these 
experiments should also be conducted in sorted populations (non-CSCs vs. 
putative CSCs and CXCR4- vs. CXCR4+).  Furthermore, in Chapter Two, we 
demonstrated that the upregulation of CXCR4 in response to microenvironmental 
stress increased the migratory and invasive potential of Ewing sarcoma cells in a 
CXCR4-dependent manner.  It is important to test the functional implication of 
CXCR4 upregulation in other tumor types such as proliferation, migration, and 
invasion.  Should our hypotheses be correct, addressing the epigenetic plasticity 
of CXCR4 and its impact on CSC biology highlights the importance of developing 
therapeutic interventions targeting CXCR4 activation. 
 
Is CXCR4 responsive to other stresses? 
 In Chapters Two and Three, we demonstrated that CXCR4 is upregulated 
in Ewing sarcoma in response to serum deprivation, hypoxia, and growth 
constraints.  While these stresses are relevant, they are only a fraction of the 
conditions tumor cells face in their in vivo microenvironment.  In addition to 
growth factor and nutrient deprivation, Ewing sarcoma tumors are bombarded 
with cytotoxic agents and radiation as part of standard treatment protocols (23-
27).  Despite great successes in treating cancer with chemotherapy and 
radiation, the challenges have been identifying the population of tumor cells that 
will survive, spread, and repopulate after initial therapy (28).  CXCR4+ cells have 
been implicated as populations of cells that survive therapy and contribute to 
tumor relapse.  In pediatric acute myeloid leukemia (AML) cell lines, CXCR4 
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expression was increased after treatment with conventional chemotherapy 
therapy (29).  In addition, gemcitabine induced CXCR4 expression in pancreatic 
cancer, promoting tumor cell invasion (30).  Lastly, non-small cell lung cancer 
cells that survived ionizing radiation treatment displayed an increase in CXCR4 
expression (31).  Collectively, these data suggest that the upregulation of CXCR4 
after treatment with chemotherapy or radiation may be a mechanism of 
therapeutic resistance. 
For Ewing sarcoma patients, up to a third of patients who present with 
localized disease will relapse at distant sites following an initial clinical remission.  
Are the cells that survive initial treatment and contribute to disease relapse 
CXCR4+ in Ewing sarcoma?  We hypothesize that chemotherapy-induced 
upregulation of CXCR4 Ewing sarcoma cells is a mechanism of therapeutic 
resistance.  To test this hypothesis we would subject Ewing sarcoma cell lines to 
chemotherapeutic agents that are commonly used in the treatment of Ewing 
sarcoma patients.  The current protocol for Ewing sarcoma includes vincristine, 
doxorubicin, and cyclophosphamide (VDC), alternating with ifosfamide and 
etoposide (IE) (26, 32).  We would test a variety of drug combinations and dosing 
regiments in a panel of Ewing sarcoma cell lines to assess any changes in that 
may occur in CXCR4 expression.  Additionally, Ewing sarcoma cells could be 
subjected to varying doses of gamma irradiation to determine its effect on 
CXCR4 expression.  Surface CXCR4 and mRNA expression would be 
determined by flow cytometry and qRT-PCR, respectively. 
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If our hypotheses stand correct, and CXCR4 is upregulated in response to 
chemotherapy, we would want to assess the mechanisms underlying this 
upregulation. Given our focus in Chapter Three on the epigenetic regulation of 
CXCR4 plasticity, we hypothesize that the upregulation of CXCR4 as a means of 
therapeutic resistance is epigenetically mediated. To test our hypothesis, we will 
perform ChIP experiments as described in Chapter Three, to compare changes 
in histone modifications at the CXCR4 locus in chemotherapy naïve cells and 
chemotherapy resistant cells.  Additionally, since CXCR4 overexpression has 
been shown to promote migration, invasion, and metastatic potential of many 
tumor types, we would assess whether cells that have upregulated CXCR4 and 
survived chemotherapy have increased migration and invasion potential (33-38).  
These experiments would be conducted using the xCELLigence system as 
described in Chapters Two and Three.  We predict that the cells treated with 
chemotherapy will upregulate CXCR4, which in turn will promote Ewing sarcoma 
cell migration and invasion.  Furthermore, we predict that the upregulation of 
CXCR4 is, in part, epigenetically regulated through a bivalent promoter.  We plan 
to extend these studies to other tumor types like breast cancer and glioblastoma.  
  
Can novel approaches be used to target CXCR4 for cancer therapy? 
 Targeting the CXCR4/CXCL12 signaling axis is highly appealing and has 
generated a great deal of interest due to the vast roles it plays in cancer 
progression, in a multitude of tumor types (39, 40).  The first CXCR4 inhibitor to 
enter clinical trials was AMD3100, which was originally developed for the 
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treatment of HIV.  In 2008, AMD3100 was FDA approved in combination with G-
CSF for autologous HSC mobilization for patients with non-Hodgkin lymphoma 
and multiple myeloma (41).  CTCE-9908, a small peptide antagonist for CXCR4 
was approved in 2005 for orphan drug status for the treatment of osteosarcoma 
(42).  In addition to these two compounds, there are many clinical trials underway 
with CXCR4 pathway inhibitors (43-45).  Despite these efforts to generate 
CXCR4 targeted therapies, very few drugs have been successfully implemented 
in the clinic. 
 Our findings in Chapter Three suggest a new, potentially promising 
approach to targeted CXCR4 inhibition.  We have demonstrated a critical role for 
epigenetically determined cell plasticity in Ewing sarcoma.  In Chapter Three, we 
demonstrated that the treatment of Ewing sarcoma with subcytotoxic doses of 
the enhancer antagonist, JQ1, blocked CXCR4- to CXCR4+ cell state transitions 
as well as inhibited CXCR4-mediated migration and invasion.  These findings 
open the door to novel therapeutic approaches that exploit the potential of 
epigenetic modifiers as adjunct therapies that antagonize plasticity and thereby 
minimize tumor cell heterogeneity.   
Given that cancer cells are exquisitely dependent on epigenetic pathways, 
the use of epigenetic modifiers, as pharmacologic agents is of great interest.  
Currently, the DNMT inhibitors, 5-azacitidine and decitabine, are approved for the 
treatment of myelodysplastic syndrome (MDS).  Additionally, the HDAC 
inhibitors, vorinostat and romidepsin are approved for cutaneous T-cell 
lymphoma (CTCL) (46).  Unfortunately, there are no epigenetic modifiers that are 
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currently approved for pediatric cancers, however, the approval of the above 
inhibitors provides hope that after the necessary preclinical data, the use of 
epigenetic modifiers may be clinical approved for the treatment of pediatric 
cancers.  
 A key challenge for future epigenetic therapies will be determining the 
appropriate time of administration in the clinic. Current studies suggest that 
epigenetic modifiers are most effective in combination with other anti-cancer 
strategies (47).  Additionally, it will be of great importance to verify that these 
global epigenetic modifiers have no deleterious effects.  In Chapter Three, we 
used the EZH2 inhibitor, GSK-126, to confirm that the loss of H3K27me3 
enrichment we were seeing in response to serum deprivation and hypoxia was 
mediated directly through EZH2.  Treatment with subcytotoxic doses of GSK-126 
resulted in a marked upregulation of CXCR4 and was accompanied by a 
dramatic decrease in the enrichment of H3K27me3 at the CXCR4 promoter.  
Given the critical role of CXCR4 in promoting proliferation, migration, and 
invasion, the upregulation of CXCR4 is not desired outcome.  These data provide 
a cautionary tale to the use of epigenetic modifiers, which may activate or 
repress unintended targets.  Despite our findings, pharmacological inhibition of 
EZH2 has been developed as a therapeutic strategy for the treatment of 
lymphomas with EZH2 mutations (48). 
 
SUMMARY 
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In summary, the work conducted in this thesis demonstrates a role for 
CXCR4 in Ewing sarcoma pathogenesis.  We show that CXCR4 is 
heterogeneously expressed in Ewing sarcoma cell lines and tumors ranging from 
absent to high-level expression.  Interestingly, we noted that in Ewing sarcoma 
cells, CXCR4 expression is highly plastic and dynamic in response to changes in 
the microenvironment, which leads to the emergence of a population of cells that 
possess increased migratory and invasive potential.  In addition, we 
demonstrated that the dynamic regulation of CXCR4 is governed, at least in part, 
by epigenetic plasticity at the CXCR4 locus.  Specifically, the CXCR4 promoter 
resides in a bivalent state and in response to changes in the microenvironment is 
converted from a bivalent repressed state to a univalent, active state, which is 
mediated by the loss of the repressive histone modification, H3K27me3.  
Furthermore, an enhancer upstream of CXCR4 also contributes to its regulation.  
In support of this, we demonstrated that JQ1, an inhibitor of enhancer function, 
antagonizes CXCR4 state transitions as well as inhibits CXCR4-mediated Ewing 
sarcoma cell migration and invasion.  Together, these studies reaffirm the 
importance of the CXCR4/CXCL12 signaling axis in cancer and the potential 
clinical implications of targeting this axis for the treatment and prevention of 
cancer progression. 
This thesis has provided a foundation for understanding the role of 
CXCR4 in Ewing sarcoma metastasis.  Of significance, this thesis contributes to 
the growing literature demonstrating the role of epigenetic mechanisms 
regulating tumor heterogeneity and cancer cell plasticity. 
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